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ABSTRACT OF THE DISSERTATION
THE INFLUENCE OF GENE ENVIRONMENT INTERACTION ON THE RISK OF
COGNITIVE IMPAIRMENT: REDUCING SEXUAL RISK BEHAVIORS AND
ALCOHOL USE IN HIV-INFECTED ADULTS
by
Karina Villalba
Florida International University, 2014
Miami, Florida
Professor Jessy G. Dévieux, Major Professor
Memory deficits and executive dysfunction are highly prevalent among HIV-infected
adults. These conditions can affect their quality of life, antiretroviral adherence, and HIV
risk behaviors. Several factors have been suggested including the role of genetics in
relation to HIV disease progression. This dissertation aimed to determine whether genetic
differences in HIV-infected individuals were correlated with impaired memory, cognitive
flexibility and executive function and whether cognitive decline moderated alcohol use
and sexual transmission risk behaviors among HIV-infected alcohol abusers participating
in an NIH-funded clinical trial comparing the efficacy of the adapted Holistic Health
Recovery Program (HHRP-A) intervention to a Health Promotion Control (HPC)
condition in reducing risk behaviors.
A total of 267 individuals were genotyped for polymorphisms in the dopamine
and serotonin gene systems. Results yielded significant associations for TPH2, GALM,
DRD2 and DRD4 genetic variants with impaired executive function, cognitive flexibility
and memory. SNPs TPH2 rs4570625 and DRD2 rs6277 showed a risk association with
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executive function (odds ratio = 2.5, p = .02; 3.6, p = .001). GALM rs6741892 was
associated with impaired memory (odds ratio = 1.9, p = .006). At the six-month followup, HHRP-A participants were less likely to report trading sex for food, drugs and money
(20.0%) and unprotected insertive or receptive oral (11.6%) or vaginal and/or anal sex
(3.2%) than HPC participants (49.4%, p <.001; 22.5%, p=.05; 15.4%, p=.04). Results
also showed that impaired cognitive flexibility and visual memory were associated with
increased alcohol use (F = 1, 3.82, η2 = 0.03, p = .05; and F = 1, 5.79, η2 = .05 p = .02),
respectively. These findings provide evidence that dopamine and serotonin
polymorphisms influence executive function and memory as well as moderate alcohol
use and that HHRP-A was effective in reducing sexual transmission risk behaviors in
HIV-infected alcohol abusers.
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CHAPTER I
BACKGROUND
A. Introduction
The development of combination antiretroviral therapy (ART) has mitigated the
severity of the human immunodeficiency virus (HIV) epidemic. Therapeutic advances
have transformed HIV/AIDS from a life-threatening illness to a chronic condition.1
Despite substantial improvements in life expectancy and a lower incidence of HIVassociated neurocognitive disorders (HAND), neuropsychological and neurocognitive
deficits continue to be highly prevalent.2 Clinical neurocognitive manifestations of
HAND in the ART era differ from the typical AIDS dementia complex.1 In the pre-ART
era, a progressive subcortical dementia with motor and cognitive slowing was common.
However, today more cortical than subcortical involvement is often reported.3, 4
The AIDS Task Force of the American Academy of Neurology (AAN) developed
the Frascati criteria which categorized HAND into three conditions.3 These conditions are
based on the number of cognitive domains impaired and the level of interference in
everyday life. These conditions are asymptomatic neurocognitive impairment (ANI),
mild neurocognitive disorder (MND) and HIV-associated dementia (HAD).5 Although
the incidence of HAD has declined, prevalence rates of HAND driven by ANI have
increased due to increased longevity of affected patients.5 ANI is defined as impairment
in at least two cognitive domains with one standard deviation below the mean and no
impairment in activities of daily living.5 Neurocognitive deficits continue to be a
significant problem in HIV even after the advent of ART.5 High rates of asymptomatic
neurocognitive disorder have been reported in several recent studies. For example,
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Simone and colleagues found that 60% of HIV-positive individuals on ART still suffered
from some form of neurocognitive impairment.6 Asymptomatic or minimally
symptomatic neurocognitive disorders are more prevalent in individuals in the current
ART era than in the pre-ART era.7 An epidemiological study of 1,555 HIV-infected
adults reported that 33% were diagnosed with ANI, 12% with MND and 2% with HAD.8
HAND encompasses a range of cognitive impairments, including slowed
processing and deficient memory and attention, decreased executive function, and
behavioral changes, such as apathy or lethargy.9 Although this type of impairment is
much more subtle than the classic HIV dementia, it still affects daily function, quality of
life, antiretroviral adherence, and can increase HIV risk behaviors.10 The causes of
continuing high rates of asymptomatic neurocognitive impairment and, to a lesser degree,
mild neurocognitive disorder in the ART era are uncertain. However, the variability in
the penetration of antiretroviral drugs across the blood-brain barrier, neurodegeneration
caused by toxic inflammatory activation, and lower nadir CD4 T-cell count probably
contributed to neurocognitive decline. 5, 7, 11, 12 In addition, aging, co-infection with
hepatitis C, drug abuse, and genetic factors may act as moderators of neurocognitive
decline.5 Currently, demographic characteristics, medical comorbidities, and lifestyle
behaviors are used to identify individuals who are at risk for HAND.13 However,
additional risk factors such as the role of genetics in relation to HIV-susceptibility and
disease progression should also be examined.10 The accumulated evidence from genetic
studies suggests that cognition is heritable, leaving some individuals more vulnerable to
develop neurocognitive disorders than others.14, 15 The contribution of genetic variants
affecting the metabolism and activity of dopamine and serotonin system genes are known
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to influence these individual differences.15 Thus, investigating the association between
dopamine and serotonin-related genetic polymorphisms and neurocognitive decline is
warranted. This research determined whether specific genetic differences in HIV-infected
individuals were associated with impaired memory and executive functions, and whether
cognitive decline moderated alcohol use and sexual transmission risk behaviors.
Behavioral studies have shown convincing evidence of an intricate association between
HIV transmission risk behaviors and distal social factors. However, there is not enough
information on the effects of biological factors on HIV transmission risk behaviors as
presented below.
HHRP-A VS. HPC
SEROTONIN
SYSTEM GENES
1. SLC6A4
2. GALM
3. TPH2

DOPAMINE
SYSTEM GENES
1. DRD2
2. DRD4
3. ANKK1

OUTCOMES
A. Neurocognitive
Impairment

OUTCOMES
B. Sexual Transmission
Risk Behaviors
C. Alcohol Use

B. Genes Associated with Neurocognitive Disorders
Cognitive control processes regulating thought and action are multifaceted
functions influenced by heritable genetic factors and environmental influences.15 The
consequences of cognitive impairment are seen by the large range of both neurologic and
neuropsychiatric disorders that affect the quality of life.10, 16, 17 Cognitive impairment is
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highly heritable, and individual differences in executive function and memory are
strongly driven by genetic variations.18 A study by Friedman and colleagues indicated
that individual differences in executive function including inhibiting dominant responses,
updating working memory representations, and shifting between task sets, are almost
99% heritable.19 Additionally, evidence shows that cognition increases linearly from
childhood to adulthood by genetic modulation of environmental influences on cognitive
functioning.15 Individuals increasingly select and modify their experiences partly based
on their genetic predispositions.18, 20, 21 Cognitive neuroscience and pharmacology
associate dopamine and serotonin as neuromodulators of executive function.15
Furthermore, studies found associations between serotonin and dopamine polymorphisms
with sustained attention, memory, and executive function phenotypes in both clinical and
non-clinical populations.22-25 The most common genes associated with neurocognitive
impairment are shown in Table 1.
C. Serotonin Systems
Serotonin pathways arise from the dorsal and ventral raphe nuclei to innervate
cortical and subcortical brain regions, including the limbic forebrain, basal ganglia,
frontal cortices, thalamus, and the hypothalamus.26 The neurotransmitter serotonin, 5hydroxytryptamine (5-HT), is implicated in the pathophysiology of several
psychological, behavioral, and psychiatric disorders.27 Low 5-HT in the central nervous
system probably influences impulsivity, aggressive behaviors, increase use of alcohol,
and risky health behaviors.28 The serotonin transport gene SLC6A4 is one of the most
extensively studied genes in the serotonergic pathway.22, 29 SLC6A4 encodes the serotonin
transporter gene that affects serotonergic neurotransmission by reuptake of synaptic
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serotonin, ending neurotransmission.30 Polymorphisms within SLC6A4 are known to
influence memory regulation, decision making, and response inhibition.14, 27, 31 In
addition, twin studies have shown an additive genetic influence on measures of sustained
attention.32, 33
The tryptophan hydroxylase isoform 2, TPH2, is a promising candidate gene for
cognitive functioning because it is the rate-limiting enzyme of 5-HT synthesis.24 The
single nucleotide polymorphism (SNP) rs4570625 may lead to increased risk of
depression, attention-deficit hyperactivity disorder (ADHD), autism, and suicide.34-36
Evidence of TPH2 gene variations playing a role in cognition comes from studies
implicating TPH2 in the pathophysiology of ADHD and obsessive-compulsive
disorder.36-38 A recent study showed that the SNP rs4570625 on TPH2 was associated
with impaired executive control.39 Another study, on homozygous TT genotype on SNP
rs4570625, showed low anxiety and high extroversion, indicative of low impulse control,
which can be correlated to lower prefrontal executive control performance.24
D. Dopamine Systems
Dopamine is a neurotransmitter that regulates functional network activities in
various regions of the brain. Dopamine neurons are located in the ventral midbrain and
the diencephalon.40 Dopaminergic neurons send projections to the frontal cortex, globus
pallidus, striatum, and nucleus accumbens, and are involved in several cognitive
functions influencing performance, motor control, reward, and cognition.41, 42 Dopamine
and serotonin systems modulate executive function by co-jointly adjusting neurochemical
transmission in the prefrontal cortex (PFC).15 The PFC plays a central role in top-down
control of many higher-order executive tasks. It is involved in learning, memory,
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categorization, inhibition control, and cognitive flexibility.43-45 Activation of D1, D2, D3,
and D4 receptors modulate the excitability of receptor cells and PFC neural network
activity. 46 The dopamine D2 receptor gene, DRD2, is one of the most extensively
investigated genes associated with dopamine receptor function, with the TaqIA
polymorphism being the most frequently studied.46, 47 The D2 receptor of the DRD2 gene
is associated with PFC mediated behaviors including attentional control, planning, and
verbal reasoning.47 Other areas include visuospatial performance and cognitive
flexibility.48
The dopamine D4 receptor is widely expressed in the CNS, particularly in the
frontal cortex, hippocampus, amygdala and hypothalamus.33, 49 The DRD4 gene is located
on chromosome 11p15.5 and has a highly variable number of tandem repeats (VNTR) in
the coding sequence.23, 50 The three most common polymorphic variants of the receptor in
the human population are D4.4, D4.7 and D4.2. However, they are functionally and
pharmacologically nearly indistinguishable from each other.51, 52 Individuals with D4.7 or
more repeats show both reduced binding affinities and receptor densities for dopamine
neurotransmission.53 Several studies have analyzed the association between the D4.7repeat allele in DRD4 gene and ADHD.23, 33 The D4.7 repeat correlates with impulsivity
and lower levels of response inhibition.54 Table 2 shows significant associations found in
the literature and relevant to this review.
E. HIV-associated Pathologies in Dopamine and Serotonin Systems
HIV neuropathology is widespread in both the cortical and subcortical brain
regions.13 HIV enters the CNS through infected macrophages/monocytes early in the
course of infection and the virus resides primarily in microglia and macrophages.55
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Microglia and macrophages are the only resident CNS cells capable of increasing HIV
infection in the brain.56 The infection of these cells leads to a cascade of neurotoxic
events that damage neurons through the production of secreted viral neurotoxins,
neuroinflammation, myelin degradation, and the breakdown of the blood-brain barrier.57
HIV-related neuropathology is particularly prevalent in areas of the frontal lobes and
subcortical structures, especially the putamen and caudate nuclei, the hippocampus, basal
ganglia and substantia nigra.2, 58, 59 Specifically, there is a significant decrease in the
levels of homovanillic acid in the cerebrospinal fluid of AIDS patients, results that are
probably related to loss of dopamine cell bodies in post-mortem tissues of these
patients.60
F. HIV-associated Neurocognitive Disorders
Behavior encompasses three functional systems: cognition, emotionality, and
executive function.61 HIV infection can disrupt all three of these functional systems.5
Cognition is the ability to select, classify, and integrate information. It also includes
information storage, retrieval, mental organization, and recognition of information.61
Executive function is part of a system that acts in a supervisory capacity of the brain
through planning, decision-making, and response control for purposeful goal-directed
behavior. 62 Memory is a subclass of cognitive function, divided into long-term and shortterm (working) memory. Long-term memory is further divided into explicit and implicit
memory as shown in Figure 1.63 Neuropsychological studies have shown an association
between HIV-associated neurocognitive impairment and dysfunction of frontostriatal
circuits that mediate processing speed, working memory, and executive function.64-66 For
example, these patients suffer from impairment of episodic memory and visual memory,
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as well as affective and cognitive-emotional processing.67 Other studies have documented
limited use of higher level encoding strategies, such as semantic clustering and strategic
retrieval that may negatively impact medication adherence and cause poor work-related
performance.68, 69 Normal executive function is dependent on the structural and functional
integrity of the dorsolateral parietal cortex.70 Executive dysfunction and poor cognitive
flexibility are the most prevalent neurocognitive impairment among HIV-infected
adults.71-73 Risky decision making is also affected by HIV infection that can impact
frontostriatal circuits and subcortical regions.74 For example, HIV-infected adults have
the propensity to choose larger immediate rewards over gradually-accumulated smaller
rewards that result in overall long-term gains.74 These observations suggest that HIVinfected adults make more impulsive and risky decisions in their daily lives (e.g., failure
to use a condom).5
G. HIV-associated Risky Behaviors
Recent studies suggest that, in addition to opiates, cocaine, and
methamphetamine, alcohol, cannabinoids, and tobacco may also influence the effects of
HIV on the brain.75 HIV-infected substance abusers are more prone to rapid progressive
illness with higher viral loads, decreased immune suppression, and increased cognitive
impairments compared to HIV-infected non-substance abusers.76 In addition, an
established trend of high-risk behaviors, often associated with depression is observed in
this population.77 HIV-infected substance abusers are more likely to be non-adherent with
antiretroviral medication, a factor that may account for worsening cognitive function, and
more rapid disease progression.78
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There is a high level of comorbidity of alcohol dependence and HIV infection.79,
80

For example, the rate of heavy drinking among HIV-infected adults is almost twice that

of the general public.81 HIV-infected individuals who abused alcohol showed a nine fold
increase in medication noncompliance compared to HIV-infected non-alcohol abusers.82
Chronic alcohol use is characterized by compulsive and obsessive behaviors which can
negatively activate the mesolimbic dopamine reward system and influence the effects of
serotonin in the brain.83, 84 Abnormal dopaminergic transmission is considered one of the
pathogenic mechanisms of alcohol dependence.85 Dopamine is thought to mediate reward
mechanisms in mesolimbic neurons and numerous studies have focused on genes related
to dopamine function.41, 46 In contrast, the serotonergic system is believed to modulate
alcohol craving and drinking behavior.86 Alcohol exposure alters several aspects of
serotonergic signal transmission in the brain.87
The effects of chronic alcohol use on cognitive function are greater for current
consumption, higher quantities, longer duration, and older age.82 A clinical study
evaluated the effect of regular daily consumption of six or seven standard alcoholic
drinks and found a moderate association with cognitive impairment.88 Clinical studies
show that not all chronic drinkers are at equal risk for brain changes; most suffered mild
cognitive impairment which can improve within a year of abstinence.89, 90 Findings on the
effects of alcohol abuse and HIV infection are mixed. Some studies have demonstrated
that alcohol abuse and HIV infection have independent effects on cognitive function91, 92
while others have proposed the possibility of increased vulnerability to cognitive
impairment due to an interaction between chronic alcohol use and HIV infection.79, 93
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Although healthcare practitioners have turned to antiretroviral therapies to avert
new infections and to slow down HIV disease progression, alcohol can pose a serious
challenge to HIV treatment and prevention.94 Furthermore, alcohol may interfere with the
prevention of HIV transmission by impeding ART adherence and increasing the risk for
sexual risk behaviors.95 Heavy alcohol consumption impairs judgment and cognition
which in turn diminishes the perception of risk, leading to unsafe sexual practices and
increased risk of HIV transmission.96 Furthermore, one in three HIV-infected alcohol
abusers engaged in unprotected vaginal or anal intercourse with an uninfected partner in
the last year.94 A meta-analysis assessing the association between alcohol and
unprotected sex, based on diverse indicators of alcohol consumption (global, situational
and event-level), showed significant associations with alcohol use and unsafe sexual
practices.98
Intervention studies focusing on alcohol use are important due to the wide
spectrum of problems associated with sexual transmission risk and antiretroviral
adherence among HIV-infected individuals.99 In general, behavioral interventions are
designed to improve HIV treatment adherence and to reduce unsafe sexual practices.
Evidence shows that risk reduction interventions are more effective for participants who
are not chronic alcohol users.100, 101 Alcohol use threatens the success of intervention and
prevention programs and should be addressed when developing programs for HIVinfected individuals.
H. Significance
Asymptomatic neurocognitive impairment remains a challenge during the ART
era.1 Memory deficits and executive dysfunction are highly prevalent among HIV-
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infected adults.8 These conditions can affect their quality of life, antiretroviral adherence,
and HIV risk behaviors.5 The causes of asymptomatic neurocognitive impairment are still
unclear. However, several factors have been suggested including the role of genetics in
relation to HIV disease progression.5 It is suggested that among HIV-infected adults who
suffer from impaired cognition, genetically determined polymorphisms in dopamine and
serotonin-related genes, may amplify differences in cognitive performance measures
compared to healthy subjects. Cognitive functions are influenced by the serotonin and
dopamine systems. Thus, genetic differences in the serotonin and dopamine system genes
may exacerbate the development of neurocognitive impairment in an individual.1, 5, 15
Behavioral studies have shown evidence of an intricate association between HIV
transmission risk behaviors and distal social factors. However, there is not enough
information on the effects of biological factors on HIV transmission risk behaviors. This
dissertation hypothesizes that serotonin and dopamine-related gene polymorphisms
compounds the HIV-associated vulnerability to deficits in executive function, cognitive
flexibility and memory and these cognitive impairments moderate alcohol use and sexual
transmission risk behaviors.
I. Statement of Aims and Hypotheses
Specific Aim 1: To investigate whether serotonin-related polymorphisms (SLC6A4 5HTTLPR, TPH2 rs4570625 and GALM rs6741892) are associated with impaired
executive function and memory.


Hypothesis 1: Serotonin-related polymorphisms are associated with impaired
executive function and memory in HIV-infected alcohol abusers.

Specific Aim 2: To investigate whether dopamine-related polymorphisms (DRD4 D4,
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ANKK1 rs800461, and DRD2 rs6277) are associated with impaired cognitive flexibility
and executive function.


Hypothesis 2: Dopamine-related polymorphisms are associated with impaired
cognitive flexibility and executive function in HIV-infected alcohol abusers.

Specific Aim 3: To evaluate the effectiveness of the adapted Holistic Health Recovery
Program (HHRP-A) on reducing alcohol use and HIV sexual transmission risk and to
explore whether cognitive impairment moderates alcohol use and sexual transmission
risk.


Hypothesis 3A: Participants in the experimental group will show a greater
reduction in alcohol use and sexual transmission risk than participants in the
comparison group.



Hypothesis 3B: Cognitive impairment moderates alcohol use and sexual
transmission risk in HIV-infected alcohol abusers.
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Table 1. Serotonin-and dopamine-related genes associated with cognitive functions
Neurotransmi
tter

Gene

Genetic
variant

DRD4

VNTR
exon 3

Dopamine

DRD4

VNTR
exon 3

Serotonin

TPH2

rs457062
5

TPH2

rs457062
5

Serotonin

SLC6A
4

5HTTLP
R

Serotonin

SLC6A
4

5HTTLP
R

Dopamine

Serotonin

Serotonin

SLC6A
4

VNTR
intron2

Molecular
association
7-repeat allele
associated with
decreased dopamine
ability to inhibit camp
formation
7-repeat allele
associated with
decreased dopamine
ability to inhibit
cAMP formation
TPH associated with
regulation of
serotonin availability
TPH associated with
regulation of
serotonin availability
L allele associated
with increased 5-HT
uptake compared to S
allele
L allele associated
with increased 5-HT
uptake compared to S
allele
STin2-polymorphisms
as transcriptional
regulators

Cognitive
test

Cognitive
association

Go/NoGo
task

4-repeat allele
showed less
accurate response
inhibition

Stop-signal
task

Adults with the 7repeat allele
displayed impaired
inhibition

fMRI image
test

T allele associated
with impaired
executive control

Working
memory task

G allele associated
with fewer errors

Continuous
performance
task
Working
memory task
Trial making
test, Rey
auditory
verbal
learning test

L allele associated
with higher rates of
omission and
commission rates
S/S genotype
associated with
higher error-rate
performance
Homozygous
STin2.10 associated
to cognitive
dysfunction in
depressed adults

5-HT, serotonin; SLC6A4, serotonin transporter; DA, dopamine; DAT1, dopamine transporter 1; DRD2:
dopamine receptor D2; DRD4, dopamine receptor D4; fMRI: functional magnetic resonance imaging;
SNP, single nucleotide polymorphism; TPH, tryptophan hydroxylase; VNTR, variable number tandem
repeat.
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Table 2. Characteristics of the most studied SNPs associated with the risk of cognitive
decline and dementia
Chromosome
nucleotide
position

Gene

Genotype

MAF*

SNP-risk allele

PMID**

Chr.19:44892362

TOMM40

A/G

G = 0.1336

rs2075650

23207651102

Chr. 8:65732478

MTFR1

A/G

G = 0.3641

rs10808746

23535033102

Chr. 19:44906745

APOE

A/G

A = 0.0822

rs769449

24468470103

Chr. 2:127137039

BIN1

C/T

G = 0.3714

rs744373

19734903103

Chr. 6:47484534

CD2AP

C/T

C = 0.1905

rs9296559

21460840103

Chr. 6:129476939

LAMA2

C/T

C = 0.2461

rs2571577

23535033104

Chr. 13:85634269

SLC8A1

C/T

C = 0.1322

rs9602785

23535033104

Chr. 13:85634269

SLTRK6

C/T

C = 0.1322

rs9602785

23535033104

Chr. 21:45621894

PCBP3

G/T

T = 0.1538

rs11701130

23535033105

Chr. 7:143412046

EPHA1

C/T

C = 0.1878

rs11767557

21460840105

Chr. 2:136957689

PICALM

A/G

T = 0.3297

rs3851179

19734902106

Chr. 2:136957689

THSD7B

C/T

C = 0.3880

rs524398

23535033106

Chr. 8:27607002

CLU

C/T

T = 0.3848

rs11136000

19734902106

Chr. 1:207518704

CR1

A/G

A = 0.0877

rs6656401

19734903107

Chr. 19:51224706

CD33

G/T

A = 0.2378

rs3865444

21460840107

Chr. 11:6013029

OR56A1

C/T

C = 0.2195

rs10769565

23535033107

Chr. 5:11043805

CTNND2

A/T

T = 0.3030

rs2973488

23535033108

*Genome Reference Consortium Human Build 37 patch release 10 (GRCh37.p10) used for nucleotide
position (http://www.ncbi.nlm.nih.gov/SNP/)
**PMID PubMed Identification Number
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Figure 1. Types of human memory
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Short-term Memory
(working memory)

Long-term Memory
(lifetime)
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(conscious)

Implicit
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Declarative Memory
(facts, events)

Procedural
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tasks)

Episodic Memory
(events, experiences)
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Semantic Memory
(facts, concepts)

CHAPTER II. METHODS
A. Data Source
Data collected from the study entitled "Intervening with HIV+ Alcohol Abusers:
Influence of Neuro-Behavioral Factors" were used to examine the research aims in this
dissertation. The main study was a longitudinal (12 month follow-up) randomized
controlled trial designed to reduce HIV sexual transmission risk and substance use,
increase the utilization of primary HIV care services and to improve psychosocial health
among a sample of HIV-infected alcohol abusers.
The experimental condition was an adaptation of the Holistic Health Recovery
Program (HHRP), an evidence-based intervention guided by the Information-MotivationBehavioral skills (IMB) model.1 The HHRP program was originally designed for drug
abusing populations (See Appendix 1).2 However, the main study from which this
dissertation is derived, used and adapted version (HHRP-A) of the original evidencebased intervention specifically tailored for alcohol abusing populations.
1. Recruitment and Informed Consent
Recruitment was conducted in multicultural, low income, urban areas of MiamiDade County. These areas are known for their high rates of alcohol and other drugs of
abuse, HIV, poverty and lack of health insurance. Thirteen community-based
organizations (CBOs) serving the target population agreed to act as recruitment sites.
These CBOs were among the largest in Miami-Dade providing outpatient treatment
programs for alcohol and other drugs of abuse and mental health services to HIV-positive
men and women. Recruiters screened interested potential participants to determine
eligibility and proceeded to the informed consent process if all eligibility criteria were
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met. The recruiter met each potential participant in a private space and explained the
study procedures, the intervention and assessment protocols, the follow-up periods, the
confidentiality and compensation. A separate consent form was presented to eligible
participants to solicit their participation in the genetic testing and blood draw. They were
informed that they could decline to participate in the intervention study or the blood draw
and withdraw at any time without adverse consequences.
Since this study collected highly sensitive clinical data, multiple layers of
protection for confidentiality were developed: First, a Data Safety Monitoring Board was
established for this project. Second, only the participant’s number was used on the data
collected thus, making it impossible to link a specific participant to questionnaire and
genotype data collected. Only the Principal Investigator and project coordinator had
access to the password protected and encrypted database linking participants’ names and
numbers. Finally, a Certificate of Confidentiality was obtained from the National Institute
on Alcohol Abuse and Alcoholism.
The inclusion criteria were: between 18 and 60 years old, HIV-positive and
willing to present documentation to confirm serostatus, consumed alcohol in the last 3
months with a history of alcohol abuse or dependence within the past 2 years, and at least
one episode of unprotected vaginal or anal sex in the past 90 days. Additional criteria
included: ability to understand and speak English, ability to understand the informed
consent, and ability to provide contact information to facilitate being located for followup interviews. Other inclusion criteria included willingness to be randomized to the
experimental or control group, not facing immediate incarceration or residence in a
restricted environment, and currently not showing overt signs of major psychiatric
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disorder. As previously mentioned, blood specimen collection for the study was optional
and subject to informed consent. See appendix 2 for further information on the CBOs.
2. Group Randomization
Once participants completed the baseline assessment, they were entered into the
study in groups of eight of the same sex. The groups of participants were assigned to
receive either the experimental or control condition, using a randomized block design,
based on a computer-generated random sequence assignment. Random sequencing was
used to control for bias in subject assignments across conditions. To prevent cross-group
contamination participants were recruited from different locations. Each cohort was
staggered in time to reduce the possibility of interaction and to prevent discussion of their
experiences with participants from different cohorts.
3. Treatment Condition: HHRP-A
HHRP is an evidence-based program designed to promote risk reduction
behaviors among HIV-positive individuals.2 While the original intervention (HHRP)
included twelve weekly group sessions, the adapted intervention (HHRP-A) included
eight, two-hour sessions, delivered twice a week, for four weeks. Some of the topics
discussed were: setting and reaching goals, reducing risk behaviors, preventing relapse,
adherence to antiretroviral treatment, and coping with stigma and grief. There was an
emphasis on relaxation and coping skills training designed to reduce negative mood, and
build positive social support networks with peers. Cognitive remediation strategies were
incorporated because of the potential for cognitive impairment in this population. Some
of these strategies were repetition and review, behavioral games, memory books,
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reduction of distraction and fatigue, as well as an ongoing assessment of learned
materials with immediate feedback.3
4. Treatment Condition: Health Promotion Comparison
The Health Promotion Comparison (HPC) condition focused on educational and
didactic methodologies, addressing common health problems such as nutrition, physical
fitness, smoking avoidance/cessation and healthy living. HPC did not incorporate
behavioral skills training or motivational enhancement techniques. HPC matched HHRPA in total administration time and format (eight, two-hour sessions). However, the
program was condensed and delivered in two days, to reduce the risk of cross-group
contamination and the potential for enhancing social support that group sessions repeated
over time could engender. A session offering standard care of HIV education was
included in the HPC program. It was unethical not to include an HIV education in the
comparison group, given the high-risk nature of this population.
B. Materials
1. Selection of Genetic Markers
A group of genetic markers known to correlate with cognitive function was used.
Serotonin-and dopamine-related genes were selected using the medical literature which
was reviewed for associations with cognitive function.4-7 The following genes were: 1)
solute carrier family 6 (neurotransmitter transporter, serotonin), 2) member 4 (SLC6A4),
3) dopamine receptor D2 (DRD2), 3) dopamine receptor D4 (DRD4), 4) galactose
mutarose , aldose 1-epimerase (GALM), 5) solute carrier family 6 (neurotransmitter
transporter, dopamine) member 3 (SLC6A3), 6) ankyrin repeat and kinase, domain
containing 1(ANKK1) and 7) tryptophan hydroxylase isoform 2 (TPH2). 8-15 The chosen
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polymorphisms were further divided into two categories: single nucleotide
polymorphisms (SNPs) and variable number tandem repeats (VNTR). A SNP is a single
nucleotide change in the DNA sequence code.16 It is the most common type of stable
genetic variation and is bi-allelic.16 VNTR is a linear arrangement of multiple copies of
short repeated DNA sequences that vary in length and are highly polymorphic, making
them useful as markers in genetic analysis.17 Tables 1and 2 include characteristics of the
genetic polymorphisms that were analyzed.
2. Genotyping
Genotyping was done by TaqMan® SNP Genotyping Assays (Foster City, CA,
USA) using the Bio-Rad CFX96™ System. Genotyping was performed blindly, without
knowledge of the clinical status of the participants. Data acquisition and analysis were
done on Bio-Rad CFX manager software (2.1). The detection method for allelic
discrimination was based on changes in fluorescence. Usually, the software assigns
specific dye fluorescence to each of the two alleles amplified, HEX-dye and FAM-dye. If
only one dye shows fluorescence then it is indicative of homozygosity. If both dyes are
detected, it is indicative of heterozygosity. Life Technologies provided data on which
allele was labeled by which dye, typically HEX (allele 1) is the major allele, and FAM
(allele 2) is the minor allele. VNTR variants were analyzed using conventional PCR. The
primers were from (Integrated DNA Technologies (IDT) Coraville, Iowa, USA). The
online IDT SciTools software Oligo Analyzer 3.0 (www.idtdna.com) was used for primer
validation. The cycling conditions for the PCR process was optimized for each template
and primer pair combination. The amplicons were run on an agarose gel with an
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appropriate molecular weight marker for size determination. For protocol details and
genetic terminology used in this dissertation see Appendices 3 and 4.
Viral load and CD4+ T cell count came from the documentation collected by the
participant’s own health care provider within one month from study intake; this
information was provided by the participant at baseline. Demographic characteristics
were also collected. Timeline Followback (TLFB) assessed sexual transmission risk,
alcohol use and other drugs. The Alcohol Use Identification Disorder Test (AUDIT)
determined alcohol use severity. Neurocognitive impairment was assessed by the
following neurological tests: The Rey-Osterrieth Complex Figure, Short Category, Color
Trail A and B, and Auditory Verbal Learning.
3. Neurocognitive Measures
The Rey-Osterrieth Complex Figure Test: It is a widely used measure for
visuospatial construction and nonverbal memory.18 It consists of a complex geometric
figure that is copied and then redrawn from memory. Accuracy of correctly copied or
recalled elements is measured based on a score from 0 to 36. The figure is divided into 18
components. Each piece is evaluated with respect to its drawing accuracy.19 This
instrument shows high test-retest reliability, with alpha scores for copy accuracy as 0.88
and for recall as 0.87.20
Auditory Verbal Learning Test: This test measures verbal memory capacity,
retrieval efficiency, and learning.21 The assessment is based on a five-trial presentation of
a 15-noun word list (list A) with a presentation rate of one word per second. A free recall
test follows each trial. On completion of trial 5, a single word presentation of a 15-noun
word interference list (list B) is presented. The test measures total learning, learning rate,
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interference measures, retention measures, and recognition measures with lower scores
indicative of greater impairment.22 This instrument demonstrates high test-retest
reliability, with alpha scores ranging from 0.51 to 0.72.23
Color Trails 1 Form A and B: The CTT is based on the use of numbered colored
circles and universal sign language symbols.24 Trail A requires the individual to connect
colored circles numbered 1-25 as fast as possible using a pencil. Trail B requires the
individual to alternate between pink and yellow colored circles numbered 2-25 as fast as
possible. The test measures the time to completion, errors, near misses and prompts.25
Trail A evaluates sustained visual attention while Trail B evaluates cognitive flexibility
The test uses the time in seconds the participant needs to complete the test, with higher
scores indicating poorer functioning.24 This instrument demonstrates high test-retest
reliability, with alpha scores ranging from 0.85 to 1.00.24
The Category Test Short Form-Booklet Format: The SCT assessment consists of
five booklets, one for each subtest, with 20 cards per subtest. All of the cards within each
subtest are organized according to a single principle. Thus, the test requires the individual
to formulate an organizing concept for each subtest. The number of errors on each
booklet is added and translated to normalized T-scores. Impairment is determined by
higher scores indicating poorer functioning.26 Test-retest coefficients range is from 0.60
to 0.96 depending upon the severity of impairment in the sample.27
4. Sexual Risk Behavior and Alcohol Use Measures
Degree of Alcohol Use Severity: AUDIT is used to measure alcohol use patterns.
The AUDIT is a 10-item survey that measures alcohol consumption, dependence
symptoms and personal and social harm reflective of drinking over the past 30 days.28
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The AUDIT score measures low-risk alcohol level from 0 to 7; high-risk alcohol level
from 8 to 15; harmful alcohol level from 16 to 19; and probably dependency level ≥ 20.28
Timeline Followback: The TLFB is a method used to obtain estimates of daily
drinking and sexual behavior.29 It uses a calendar format which helps determine
retrospective estimates of the participant's daily drinking and sexual events over the last
three months.29 TLFB was developed originally to assess alcohol use, using memory aids
to enhance recall (e.g., key dates serve as anchors for reporting drinking). This method
provides a wide range of information including pattern, variability, and the magnitude of
drinking.30 TLFB is also used for sexual behavior. The structure of the TLFB encourages
an interactive process whereby memory of one event may facilitate recall of similar or
related events.31 In addition, the TLFB method permits interviewers to obtain enriched
contextual information regarding risk behavior. This ability to provide detailed eventlevel data is especially important for research on the co-occurrence of risky behaviors.
Test-retest intraclass correlations from the TLFB showed that all sexual behaviors are
reliable, ranging from .86 to .97.31
C. Analysis
To standardize cognitive measures, standardized T-scores were developed by
using multiple linear regression methods analyzing the influence of age, sex, education,
and ethnicity on each cognitive test score. These standardized T-scores were used to
determine cognitive impairment according to the Frascati criteria,32 presented in Table 3.
Data were evaluated for potential selection bias since 112 participants did not
participate in this study. Statistical analyses were performed using Stata v.11 (StataCorp,
College Station, TX). Logistic and linear regression were used to explore the associations
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between dopamine and serotonin-related genes and cognitive impairment (executive
functioning, cognitive flexibility, memory and visual memory). The statistical threshold
was set at P < .05 and 95% confidence intervals (CIs). Ethnic and gender -specific
associations were calculated through stratified analyses. Genotyping counts were tested
for Hardy-Weinberg equilibrium (HWE) for each SNP. Associations in the overall
sample were assessed by adjusting for sex and ethnicity. By default, the additive genetic
model was used but the use of the dominant and recessive models was considered.
Data for alcohol use were transformed using the Box-Cox method.33 Data for
sexual transmission risk were analyzed using nonparametric methods. Initially, the
Wilcoxon signed-rank test was used for all the analyses. Transformed data used the t-test
and ANOVA methods to measure the outcomes. Change over time on continuous
measures was analyzed using two repeated measures analysis of variance (ANOVAs) for
treatment condition and time variables. Where change over time in any continuous
variable was detected, effect sizes (partial η2) were reported. Intervention outcomes were
assessed by alcohol use and sexual transmission risk. The outcomes were modeled as a
function of condition (intervention or control), time (baseline and follow-up), gender, and
condition by time interaction. The interaction between neurocognitive measures and
alcohol was also measured.
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Table 1: Variable number tandem repeats analyzed in the study

Polymorphism

Gene Symbol

5HHTLPR

SLC6A4

STin2

SLC6A4

DAT

SLC6A3

D4

DRD4

Gene Name

Chromosom
e

VNTR Type

17

44bp insertion/deletion

Solute carrier family
6, member 4
Solute carrier family
6, member 4
Solute carrier family
6, member 3

Dopamine
receptor D4

17 bp tandem repeat,
9,10 and 12 copies
40 bp, tandem repeat, 3
to 11 copies

17
5

48 bp tandem
repeat, 2 to 10
copies

11

bp = base pair

Table 2: Single nucleotide polymorphisms analyzed in the study
Ref-SNP ID

Gene Symbol

Rs800461

ANKK1

Rs6277

DRD2

Rs6741892

GALM

Rs4570625

TPH2

Gene Name
Ankyrin repeat and kinase
domain containing 1

Chromosome

Dopamine receptor D2

11

Galactose mutarotase aldose
1-epimerase
Tryptophan hydroxylase
isoform 2

38

11

SNP Type
Amino acid
substitution
Amino acid
substitution

2

Missense

12

5' upstream

Table 3. Categories of HIV-associated neurocognitive disorder according to Frascati
criteria
Neurocognitive status*

Functional status**

Asymptomatic neurocognitive
impairment

1 SD below the mean in
2 cognitive domains

No impairment in activities of
daily living

Mild neurocognitive impairment
or disorder

1 SD below the mean in
2 cognitive domains

Impairment in activities of daily
living

HIV-associated dementia

2 SD below the mean in
2 cognitive domains

Notable impairment in activities
of daily living

SD=standard deviation.
*Neurocognitive testing should include an assessment of at least five domains, including attention–
information processing, language, abstraction-executive, complex perceptual motor skills, memory
(including learning and recall), simple motor skills, or sensory, perceptual skills.
**No agreed measures exist for HIV-associated neurocognitive disorder criteria.
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CHAPTER III
SEROTONIN-RELATED GENE POLYMORPHISMS AND ASYMPTOMATIC
NEUROCOGNITIVE IMPAIRMENT IN HIV-INFECTED ALCOHOL ABUSERS

A. Abstract
Memory deficits and executive dysfunction are highly prevalent among HIVinfected adults. These conditions can affect their quality of life, antiretroviral adherence
and HIV risk-taking behaviors. Cognitive impairment is highly heritable and individual
differences in executive function and memory are strongly driven by genetic variations.
There is strong evidence from cognitive neuroscience associating dopamine as a
neuromodulator of executive function. However, the role of the 5-hydroxytryptamine (5HT) system, in cognition is less clear. The aim of this study was to investigate the
potential associations between single nucleotide polymorphisms (SNPs) in the serotonin
system genes and cognitive impairments in HIV-infected adults. A total of 267
biologically unrelated individuals were genotyped for polymorphisms SLC6A4 5HTTLPR, TPH2 rs4570625 and GALM rs6741892. To assess neurocognitive functions,
the Short Category, the Color Trails, and the Auditory Verbal Learning tests were used.
Results yielded statistically significant associations for TPH2 and GALM variants with
impaired executive function and memory. The SNP rs4570625 showed a significant
association with impaired executive function (odds ratio = 2.5, 95% CI, 1.1-4.9; p = .02).
The risk increased in African American males (odds ratio = 4.8, 95% CI, 1.5-14.8;
p = .005). SNP rs6741892 was associated with impaired memory (odds ratio = 1.9, 95%
CI, 1.2 - 3.1; p = .006), and again the risk increased in African American males (odds
ratio = 2.4, 95% CI, 1.2-4.9; p = .02). No significant associations were seen with the 5-
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HTTLPR polymorphism. Findings in this study suggest that TPH2 rs4570625 and GALM
rs6741892 polymorphisms in the serotonin system influence cognitive control in HIVinfected alcohol abusers.
B. Introduction
The development of ART has drastically improved HIV survival rates in the past
few decades.1 However, HIV-associated neurocognitive disorders remain highly
prevalent and continue to represent a significant public health problem.2 While the
incidence of HIV-associated dementia has declined in the ART era, around 50% of HIVinfected individuals will continue to experience some form of neurocognitive decline.
With the most prominent decline on deficient memory and attention, decreased executive
function, and behavioral changes such as apathy or lethargy.1, 3 Executive function is an
umbrella term that includes sustained attention, response inhibition, working memory,
error processing and other complex cognitive abilities.4 It is a system that acts in a
supervisory capacity, is located in the frontal lobes and coordinates complex behavior
through planning, decision-making, and response control for purposeful goal-directed
behavior.5, 6 A recent study using a cluster analysis approach showed that executive
dysfunction was the most prominent cognitive function in HIV neurocognitive
impairment and most likely to affect behavior.7
Genetic association studies have revealed statistical correlations between genetic
polymorphisms in the dopamine system and measures in executive function.8-11 Similarly,
there is increasing evidence also implicating the 5-HT system but its role in cognition is
less clear.12, 13,14 Behavioral studies have demonstrated that serotonin provides a tonic
inhibition to dopamine facilitatory effects related to several behaviors.15, 16 Similarly,
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monoaminergic neurotransmitters, including dopamine and serotonin, may interact within
cortical networks to modulate the expression of specific cognitive functions.17 For
example, studies on tryptophan depletion have proposed that 5-HT has a strong
neuromodulatory influence over the orbito-frontal-limbic network associated with
executive functions.18-20
The most widely studied genes of the serotonergic pathway are the tryptophan
hydroxylase isoform 2 (TPH2) and the serotonin transport gene (SLC6A4).21, 22
SLC6A4 encodes the serotonin transporter that affects serotonergic neurotransmission by
reuptake of synaptic serotonin, ending neurotransmission.23 Serotonin reuptake variation
is linked to a functional polymorphism in the promoter region of the SLC6A4 gene on
chromosome 17q11.1-q12.23 Polymorphisms within SLC6A4 have influenced memory
regulation, decision making, and response inhibition capabilities.14, 24, 25 In addition, twin
studies have shown an additive genetic influence on measures of sustained attention.26, 27
The TPH2 gene encodes a member of the protein-dependent aromatic acid
hydroxylase family.12 It is the rate-limiting enzyme of 5-HT synthesis in the brain, which
transforms tryptophan into 5-hydroxy-tryptophan, the direct precursor of 5-HT.28, 29 The
functional SNP rs4570625 is found within the transcriptional region of TPH2 on
chromosome 12p21.1.12 Evidence of TPH2 variations playing a role in cognition comes
from studies implicating TPH2 in the pathophysiology of ADHD and obsessivecompulsive disorder.30-32 Several studies have shown that the homozygous TT genotype
in SNP rs4570625 is associated with poorer executive control compared to GG and GT
genotypes.12, 25 Another study showed a similar association using the NoGo-
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anteriorization test, which is an index of prefrontal functioning.33 These studies showed a
compensatory adjustment of deficits in executive control functions.28, 33
Another gene of interest is galactose mutarotase (GALM). A genome wide
association study (GWAS) found a strong association between thalamic and a coding
SNP rs6741892 in GALM using the tracer [11C]DASB-BPND, used to measure brain
serotonin transporter levels. 34 The study demonstrated that SNP rs6741892 accounted for
about 50% of the variance in [11C]DASB-BPND binding potential in the thalamus,
especially for the TT genotype.34 GALM catalyzes the conversion of beta-D-galactose to
alpha D-galactose, which may affect regional neurophysiology, leading to local increases
in serotonin release in the brain.35
HIV-infected individuals continue to experience neurocognitive deterioration
despite virologically successful treatment.1 Currently, demographic characteristics and
medical comorbidities are used to identify individuals who are at risk for HAND.36 Still
the variance in HAND is not completely explained by these factors. Thus, additional
characteristics, such as genetic factors associated to HAND susceptibility, should also be
investigated.37 Genetically determined polymorphisms in serotonin-related genes may
amplify differences in cognitive performance measures in individuals already with
impaired cognition. Thus, it was hypothesized that serotonin-related genetic
polymorphism SLC6A4 5-HTTLPR, TPH2 rs4570625 and GALM rs6741892 are
associated with impaired executive control and memory. We used a number of cognitive
measures reported to be valid and reliable measures.38, 39

43

C. Methods
1. Sample
This study used baseline data gathered between 2009 and 2012 as part of a longitudinal
randomized controlled trial for HIV-infected adults who abuse alcohol and other drugs.
The main study recruited a total of 379 individuals. However, the current study used 267
biologically-unrelated individuals, because112 participants declined to provide blood for
genetic testing. Participants were between 18 and 60 years of age, HIV-positive, with a
history of drinking alcohol in the last three months, and/or a history of alcohol abuse or
dependence in the past two years. An additional inclusion criterion was not showing overt
signs of a major psychiatric disorder including psychosis or suicidality. Institutional
Review Board (IRB) approval was obtained at Florida International University prior to
the start of the study. After full explanation of the study, written informed consent was
obtained from all participants.
2. Genotyping
DNA was extracted from whole blood by manual extraction using the QIAamp
DNA Mini Kit (Valencia, CA). Genotyping for TPH2 and GALM SNPs was conducted
using TaqMan® SNP Genotyping Assays (Foster City, CA) on Bio-Rad CFX96™ realtime PCR instrument (Hercules CA). Polymerase Chain Reaction (PCR) amplifications
were performed by using the Probes Supermix, a 2X reaction buffer which contains the
necessary components for running PCR. PCR amplifications were performed using the
manufacturer's suggestion of 20μl total volume and with the following PCR thermal
cycling conditions: enzyme activation at 95ᴼC for two minutes, and 49 cycles of
denaturation at 95ᴼC for 5 seconds followed by annealing and extension at 61ᴼC for 5
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seconds. For the promoter variant called 5-HTTLPR, Bio-Rad CFX Manager software
(version 3.0) was used for data acquisition and genotype assignment. The primer
sequences used for the 5-HTTLPR amplification were obtained from a previous study.35
The sequences were as follow 5’-CCGCTCTGAATGCCAGCACCTAAC-3’ (forward
primer) and AGAGGGACTGAGCTGGACAACCAC-3’ (reverse primer) amplifying a
522-bp for the 16-repeat allele and a 478-bp- for the 14-repeat allele35. The 25 μl reaction
mixture contained: 1 x PCR amplification buffer (Qiagen, Valencia, CA), 300 μM
dNTPs, 0.5 μM of each primer, 0.5 U Taq DNA polymerase (Qiagen) and 50ng of
genomic DNA. The temperature cycle consisted of an initial denaturation at 94 ᴼC for 3
min, followed by 30 cycles of 30 s at 94 ᴼC, 30 s at 60 ᴼC and 30 s at 72 ᴼC, and final
extension for 2 min at 72 ᴼC. PCR products were separated on a 1.5% agarose gel
supplemented with gel red and visualized under UV light. All genotypings were
performed blindly, without knowing the clinical status or any background data on the
samples.
3. Neurocognitive Assessment
All participants were assessed on the same battery of neurocognitive tests and in
the same order. Verbal memory and retrieval efficiency were measured with the AVLT,
using the version World Health Organization/University of California Los Angeles
(WHO/UCLA).40 Executive function was measured with the SCT.39 and cognitive
flexibility and sustained attention were measured with the CTT Test A & B.41 Alcohol
use and other drugs of abuse were measured using the TLFB method for accurate recall
of drug consumption. AUDIT was used to determine patterns of alcohol consumption.
AUDIT is a 10-item survey that measures alcohol consumption, dependence symptoms
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and personal and social harm reflective of drinking over the past 30 days.42 The AUDIT
scores are: low-risk level (0 to 7), hazardous level (8 to 15), harmful level (16 to 19) and
possible dependency ( ≥ 20).42 There are no agreed criteria to measure HIV-associated
neurocognitive disorders. However, the Frascati criteria have been validated and is
widely used to classify HIV impairments.43 The Fracasti criteria were used to determine
cognitive impairment. Therefore, impairment in at least two domains and a cut-off of
greater than one standard deviation below the mean was used to determine asymptomatic
neurocognitive impairment 44 (Table 2, chapter 2).
Auditory Verbal Learning Test
The AVLT assessment was based on a five-trial presentation of a 15-noun word
list (list A) with a presentation rate of one word per second. On completion of trial 5, a
single word presentation of a 15-noun word interference list (list B) was presented. The
test measured retention, learning and recognition rates with higher scores representing
better episodic memory.45, 46 This instrument demonstrates high test-retest reliability,
with alpha scores ranging from 0.51 to 0.72.47
Short Category Test
The SCT assessment consisted of five booklets, one for each subtest, with 20
cards per subtest. All of the cards within each subtest were organized according to a
single principle. The test required the individual to formulate an organizing concept for
each subtest. The number of errors on each booklet was added to determine impairment
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with lower scores representing better executive function.39 Test-retest coefficients range
from 0.60 to 0.96, depending upon the severity of impairment in the sample.48
Color Trail Test
Color Trail A and B were presented. Trail A required the individual to connect
colored circles numbered 1-25 as fast as possible using a pencil. All odd-numbered
circles had a pink background while all even-numbered circles had a yellow
background.49 Trail B required the individual to start with a pink colored number one
circle and alternate between pink and yellow colored circles numbered 2-25 as fast as
possible. The test measured time to completion, errors, near misses and prompts.49 Trail
A evaluated sustained visual attention while Trial B evaluated cognitive flexibility.41 The
test used the raw time in seconds with higher scores indicating poorer functioning.41 This
instrument demonstrates high test-retest reliability, with alpha scores ranging from 0.85
to 1.00.41
D. Analysis
Statistical analyses were performed using Stata v.11 (StataCorp, College Station,
TX). Data were evaluated for potential selection bias since one hundred and twelve
participants did not participate. To standardize cognitive measures for this study,
standardized T-scores were developed by using multiple linear regression methods
analyzing the influence of age, sex, education, and ethnicity on each cognitive test score.
Each of the five cognitive domains was included as dependent variables: memory
(recognition measures form AVLT), executive function (number of errors on the SCT),
sustained attention and cognitive flexibility (time to complete the task for CTT A & B).
The continuous predictor was age, and categorical predictors were sex, education and
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race/ethnicity. All the predictors in the model were included in each regression, retaining
only the variables that significantly contributed to the prediction of cognitive test score.
These predictive scores were subtracted from each individual's actual composite score to
calculate residual scores. Finally, residual scores were converted to T-scores (mean = 50
and SD =10) which were used to determine cognitive impairment.
Logistic regression methods were used to calculate crude and adjusted odds ratios
(ORs) and 95% confidence intervals (CIs). All statistical tests were two-tailed, and the
threshold for statistical significance was set at P <.05. The ORs, with 95% CIs, were used
as a measure of effect size. Genotyping counts were tested for Hardy-Weinberg
equilibrium (HWE) for each SNP. Ethnic and gender-specific associations were assessed
through stratified analyses. Associations in the overall sample were assessed by adjusting
for sex and ethnicity/race. By default, the additive genetic model was used, but due to
previous associations in the recessive model for SCL6A4, the recessive and dominant
models were also used.
E. Results
A total of 267 HIV-infected alcohol abusers completed the study. Table 1
provides participant characteristics. The majority of the participants were men 173
(65%). Ethnicity was self-identified: 203 (76%) were African Americans, 21 (8%)
Caucasians and 43 (16%) Hispanics. The average age of participants was mean = 45.1
(SD = 7.1). The majority 190 (69%) completed high school. HIV disease markers,
including viral load and CD4 count, were not associated with AIDS diagnosis. About 128
(48%) of the participants had undetectable viral load, and a CD4 count average was 441.4
cells/mm3 (SD = 287). Lifetime alcohol use, on average, was 23.8 years in this sample.
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The mean AUDIT score was 16, and 101(38%) scored > 20. The most commonly used
drugs besides alcohol were cocaine and marijuana. However, the number of times these
drugs were used was negligible compared to alcohol use. Selection bias was not observed
since the nested study was comparable to the main study. The Frascati criteria were used
to measure neurocognitive impairment. A total of 112 (43%) participants scored below
the mean (T-score: mean = 50; SD = 10). Asymptomatic neurocognitive impairment,
greater than one standard deviation below the mean, was observed in 101 (91%) and mild
neurocognitive impairment, greater than two standard deviations below the mean was
seen in 11 (9%). Executive function and memory showed the highest impairment in this
sample (executive function: mean = 58.2 SD = 10.9; Memory: mean = 40.0 SD = 9.1).
HIV-associated dementia was not observed.
Genotyping results, including genotype frequencies are presented in Tables 2 and
3. All SNPs were in Hardy-Weinberg equilibrium. Analyses yielded significant
associations with executive function and TPH2 and memory and GALM genetic
polymorphisms. Whereas, 5-HTTLPR polymorphism did not show an association with
cognitive flexibility as previously suggested.52 The SNP rs4570625 of TPH2 gene
showed an overall association in the dominant model with impaired executive function
(odds ratio = 2.5, 95% CI, 1.1-4.9; p =.02). Furthermore, the association showed an
increased risk in males (odds ratio = 4.0, 95% CI, 1.6-10.5; p= .007), not in females
(Pinteraction = .08 for sex). Greater risk was observed in African American males (odds
ratio 4.8, 95% CI, 1.5-14.8; p = .005). For the SNP rs6741892 of the GALM gene, a
significant association with impaired memory (odds ratio = 1.9, 95% CI, 1.2-3.1;
p =.006) was observed. The risk again was increased in African American males (odds
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ratio 2.4, 95% CI, 1.2-4.9; p =.02). Results from this study showed that the associations
between serotonin-genes and asymptomatic neurocognitive impairment are male-specific.
The interaction between GALM and THP2 polymorphisms with alcohol use was nonsignificant (p = .65).
F. Discussion
This study provides further evidence for the role of 5-HT in cognition, where
functional polymorphisms of two candidate genes in the serotonergic signaling pathway
influence executive function and memory. Significant associations were found between
TPH2 SNP rs4570625 and executive dysfunction and GALM SNP rs6741892 and
impaired memory. Stratification by potential effect modifiers (sex and race) showed an
even greater effect in African American males but not in females. For the polymorphism
5-HTTLPR, no statistically significant associations were found with neurocognitive
measures. Data suggest that the 5-HTTLPR polymorphism is probably not a risk factor
for cognitive impairment and supports previous studies that reported no association
between this polymorphism and cognitive abilities or cognitive decline.50, 51 However,
other studies provided evidence of the influence of 5-HTTLPR polymorphism on
executive function. For example, a study by Rosier and colleagues evaluated the effect of
5-HTTLPR polymorphism on executive function in ecstasy users and found a significant
association with the S allele.52 Another study, observed impaired executive performance
for homozygous SS genotype compared to LL and LS genotypes in patients affected by
schizophrenia.21
The findings in this study indicate that homozygous TT genotype in SNP
rs4570625 showed higher error rates measured by the SCT than TG and GG genotypes
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implicating executive dysfunction. These findings parallel and extend those of functional
imaging and molecular genetic studies suggesting that polymorphism rs4570625 is a risk
marker for executive dysfunction. 12, 28, 30 SNP rs4570625 affects the transcription rate of
TPH2, which may increase the activity of PFC.53 The PFC plays a central role in topdown control of many higher-order executive tasks.54-56 Evidence from a functional
image study showed a significant association between SNP rs4570625 and increased
activity in several prefrontal and parietal sites during updating of working memory.28
The authors suggested that the effect of SNP rs4570625 was not specific for attention,
impulse control, or working memory, rather it seemed to reflect one common basal
cognitive process.28 Another study showed a similar association using the NoGoanteriorization test, which is an index of prefrontal functioning.33 These studies showed a
compensatory adjustment of deficits in executive control functions.33,28 Similarly, results
in this study are in line with studies suggesting increased PFC activity due to serotonin
dysregulation affecting executive function.21, 25, 57, 58 Thus, associating executive
dysfunction to a wide range of behaviors.
Behavioral studies have demonstrated that executive dysfunction (i.e., poor
learning) are central to HIV-neurocognitive impairment and most likely affects
behaviors, including adherence to antiretroviral medication and unemployment (or
underemployment).2 Heaton and colleagues found that medically asymptomatic HIVinfected adults with executive dysfunction were twice as likely to be unemployed and
perceived greater vocational difficulties than their unimpaired counterparts.59 Similarly,
another study showed that, for recently diagnosed individuals, the key predictors for
finding employment were learning and memory.60
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This study is the first to analyze the functionality of this SNP rs6741892 in
relation to 5-HT transporter. Thus, a significant association between rs6741892 and
memory measured by AVLT was found in HIV-infected alcohol abusers. The AVLT was
used because the repeated presentations of words and their successive testing at various
time intervals allowed for the analysis of different learning processes such as acquisition,
retention, retrieval, and interference.45 The thalamus plays a significant role in regulating
higher-level brain activity.61 The dorsomedial nucleus is of particular interest because of
its established role in memory and its extensive reciprocal connections with the PFC.62
Impaired explicit memory in HIV-infected adults is associated with decreased volumes of
the thalamus.63 Thus, results in this study showed a significant association with decreased
total learning, as a measure of explicit memory. Explicit memory is further divided into
semantic and episodic memory (Figure 1, Chapter 1). Semantic and episodic memory
have been associated with neurocognitive deficit in HIV-infected adults.64 Episodic
memory impairment has been associated with limited use of higher level encoding
strategies, such as semantic clustering and strategic retrieval.64 This can lead to issues
involving medication non-adherence and problematic work-related issues in HIV-infected
adults.65, 66
This study has several limitations that should be noted. First, there was relatively
low frequency of homozygous TT genotype of the TPH2 SNP. However, it should be
noted that there is relatively low occurrence of TT genotype within the general
population. In fact, compared to previous studies, the current study included a rather high
proportion of homozygous TT genotype carriers compared to others.12, 13, 53 Second, the
lack of alpha-level corrections due to multiple comparisons. However, multiple
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comparisons were necessary due to the exploratory nature of the study, including the
analysis of the SNP functionality in the GALM gene, as well as the use of all three genetic
models.
In general the additive model is used to assess statistical associations of SNPs.
While the additive model has sufficient power to detect associations in most situations,
there may be occasions where statistical significance is not found, when in fact, there is
an association. Consequently, a strength in this study was the use of multiple genetic
models to determine associations that may remain undetectable by the exclusive use of
the additive model.
G. Conclusion
The current study was the first to explore the relationship between serotoninrelated polymorphisms and asymptomatic neurocognitive impairment in a sample of
HIV-infected alcohol abusers. The results showed a significant association between
TPH2 rs4570625 and individual differences in executive function and GALM rs6741892
with memory. The two associations were male-specific. The present study validates
previous results pointing to genetic influences on executive function and memory.
Moreover, a significant association between SNP rs6741892 with memory was
demonstrated, which may imply SNP rs6741892 as a functional polymorphism in the
GALM gene affecting 5-TH transport.
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Table 1. Demographic and clinical characteristics of main and current study participants
Baseline characteristics
Age mean (DS)
Sex, No (%)
Male
Female
Education No (%)
8th grade or less
High school diploma
Some college
Race/Ethnicity No (%)
Caucasian
African-American
Hispanic
Alcohol use mean (DS)
Number of standard drinks
(past 90 days)
Lifetime
AUDIT score
Other drugs, mean (DS)
Number of times cocaine use
(past 90 days)
Number of times marijuana use
(past 90 days)
HIV Characteristics mean
(DS)
CD4 count
Viral load No (%)
Undetectable
50-10,000
10,001 - 30,000
30,000 or more
Taking ART
Cognitive measures, mean
(DS)
Executive skills T-scores
Memory skills (learning) Tscores
Memory skills (recall) T-scores
Cognitive flexibility T-scores
Sustained attention T-scores

Main study

Current study

P values

n = 112

N = 267

44.1 (7.7)

45.1(7.1)

67 (60)
45 (40)

173 (65)
94 (34)

13 (12)
73 (65)
26 (23)

19 (7)
190 (69)
57 (24)

17 (15)
80 (72)
15 (13)

21 (8)
203 (76)
43 (16)

100 (50.1)

190 (100.1)

.10

22 (10.5)
14 (7.5)

23.8 (10.9)
16 (8.0)

.24
.09

23.5 (16.8)

33.5 (19.8)

.25

19.3 (12.5)

25.6 (20.9)

.63

412.9 (318.4)

441.4 (286.9)

.73
.16

45 (40)
39 (35)
8 (7)
20 (18)
76 (68)

128 (48)
80 (30)
29 (11)
29 (11)
216 (81)

.84

50.1 (9.0)

48.2 (10.9)

.93

45.9 (10.1)

48.2 (9.1)

.18

48.1 (9.8)
40.4 (10.4)
53.9 (9.3)

40.0 (10.5)
45.7 (10.8)
56.0 (9.8)

.11
.09
.10

.66
.72
.24

.26
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Table 2. Genotype frequencies and cognitive scores for AVLT and SCT tests
Genes

SNP

Genotype

N (%)

TPH2

rs4570625

AA

93 (36%)

Cognitive T-scores
Mean (SD)
63.2 (10.1)

AB

120 (46%)

59.5 (13.3)

BB

47 (18%)

57.6 (15.1)

AA

90 (35%)

50.1 (10.2)

AB

114 (43%)

47.1 (9.0)

BB

60 (22%)

47.4 (9.8)

GALM

rs6741892
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Table 3. TPH2 and GALM associations with cognitive impairment stratified by sex and race/ethnicity
(ORs and 95% CIs)
Chra

Position

12

12:71938143

2

2:38689828

Gene
TPH2

GALM

Variant

Alleleb

rs4570625

G >T

rs6741892

A >T

Domain
Executive
function

Memory

Alleles

Sexd

Racee

Sex-Racef

2.5 (1.1 to 4.9)

4.0 (1.6 to 10.5)

3.3 (1.4 to 7.6)

4.8 (1.5 to 14.8)

P = 0.02

P = 0.01

P = 0.007

P = 0.005

1.9 (1.2 to 3.1)

2.3 (1.2 to 4.2)

1.9 (1.1 to 3.6)

2.4 (1.2 to 4.9)

P = 0.006

P = 0.009

P = 0.02

P = 0.02

Chromosomal locations are based on the Genome Reference Consortium. bAlleles are based on Genome Reference Consortium. cORs adjusted for
alcohol use, CD4 cell count, adherence to antiretroviral medication, sex and self-reported race/ethnicity. dORstratafied by sex eORstratified by race. fORstrafied by
sex and race.
Chr., chromosome; OR, odds ratio; CI confidence interval.
a
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CHAPTER IV
DRD2 AND DRD4 GENES RELATED TO COGNITIVE DEFICITS IN HIVINFECTED ADULTS WHO ABUSE ALCOHOL

A. Abstract
HIV-infected individuals continue to experience neurocognitive deterioration
despite virologically successful treatments. There is evidence suggesting that
neurocognitive impairment is heritable and individual differences in executive function
and memory are strongly driven by genetic variations. The contribution of genetic
variants affecting the metabolism and activity of dopamine may influence these
individual differences. The present study investigated the influence of two candidate
dopaminergic gene polymorphisms (DRD4 and DRD2) on executive function and
memory. They were measured by the Short Category (SCT), Color Trail (CTT) and ReyOsterrieth Complex Figure Tests (ROCT). Participants were an ethnically diverse sample
of 267 HIV-infected adults that were genotyped for polymorphisms in the DRD4 48bpvariable number tandem repeat (VNTR), DRD2 rs6277 and ANKK1 rs1800497. Results
showed significant associations with the SNP rs6277 and impaired executive function
(odds ratio = 3.6, 95% CI, 2.4-8.7; p = .001) and cognitive flexibility (odds ratio = 1.7,
95% CI, 1.3-2.6; p = .01). The results were further stratified by race and sex and
significant results were seen in males (odds ratio = 3.5, 95% CI, 1.5-5.5; p = .008) and in
African Americans (odds ratio = 3.1, 95% CI, 2.3-3.5; p = .01). In addition, DRD4 VNTR
7-allele was significantly associated with executive dysfunction. Specifically, the 7absent group performed worse than the 7-present group, in total errors committed in the
SCT. Results support the notion that dopaminergic variations influence differences in
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cognition and contribute to an understanding of the relation between genes and cognitive
impairments in HIV-infection.
B. Introduction
Human immunodeficiency virus (HIV) is a global epidemic that affects
approximately 36 million people worldwide.1 In addition to its deleterious effects on the
cell-mediated immune system, HIV can also damage cells in the central nervous system
and lead to HIV-associated neurocognitive disorders (HAND).2 The manifestations of
HAND have significantly changed in response to the introduction to antiretroviral
therapy (ART). For example, the incidence of HIV-associated dementia has declined.
However, the prevalence for asymptomatic and mild neurocognitive impairment have
increased with increased longevity.3 HAND encompasses a range of cognitive
impairment that includes deficient memory and attention, decreased executive function,
and behavioral changes, such as apathy or lethargy.4
Dopamine is a neurotransmitter that regulates functional network activities in
various regions of the brain.5 Dopamine neurons are located in the ventral midbrain and
are involved in several cognitive functions that influence performance, motor control,
reward, and cognition.5-7 Studies investigating the relationship between HIV infection
and brain pathology have revealed that the HIV virus can cause damage to dopamine-rich
areas including the basal ganglia, substantia nigra, and the frontal cortex.8-10 For example,
a neuroimaging study measured basal ganglia volume using magnetic resonance imaging
reported selective basal ganglia atrophy in adults with HIV-associated neurocognitive
disorder compared to their HIV-negative counterparts.11 Another study using the same
method showed that atrophy of the caudate nucleus was significantly associated with
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cognitive impairment in asymptomatic HIV-infected adults compared to the seronegative
control group.12
Dopamine receptors, D1, D2, D3, and D4 modulate the excitability of receptor
cells and prefrontal neural network activity.13 The SNP rs1800497 (also known as TaqIA)
of the D2 receptor gene DRD2 is one of the most extensively investigated genes in
reference to neuropsychiatric disorders.13, 14 This DRD2-associated polymorphism is
located within the coding region of a neighboring gene, ANKK1, and is associated with a
reduced number of dopamine binding sites in the brain.15 The SNP rs1800497 is located
more than ten kilobase-pairs downstream from the coding region of the DRD2 gene in
chromosome 11q23 and is, therefore, unlikely to alter DRD2 directly.16 Proximity of the
two genes may reflect functional relationship and may be associated with dopaminergic
phenotypes by being in linkage disequilibrium.17, 18 Polymorphism DRD2 SNP rs6277
has been reported to affect D2 receptor density in the striatum.19 Several studies have
shown that SNP rs6277 is associated with prefrontal cortex mediated behaviors including
attentional control, planning and verbal reasoning.14 A study on cognitive flexibility
showed that SNP rs6277 was a strong predictor for learning from negative reward
prediction errors by avoiding those responses linked to negative outcomes.17, 20
The dopamine D4 receptor is widely expressed in the CNS, particularly in the
frontal cortex, hippocampus, amygdala and hypothalamus.5, 21 The dopamine D4 receptor
DRD4 gene is located on chromosome 11p15.5 and has a highly variable number of
tandem repeats in the coding sequence.22 The polymorphism is a 48bp VNTR sequence in
exon 3, encoding the third intracellular loop of D4 receptor.23 The most common
polymorphic variants of the receptor are D4.7, and D4.4.24, 25 Individuals with D4.7
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repeat show both reduced binding affinities and receptor densities for dopamine
neurotransmission.26 The D4.7 repeat is correlated with impulsivity and lower levels of
response inhibition.27 Several studies have analyzed the association between the D4.7repeat allele in DRD4 gene and attention-deficit hyperactivity disorder (ADHD).21, 28 The
present study explores potential associations with DRD2 rs6277, ANNK1 rs1800497 and
DRD4 48bp VNTR polymorphism and cognitive functions in HIV-infected alcohol
abusers.
C. Methods
1. Participants
This study utilized a cross-sectional design, using baseline data gathered between
2009 and 2012 as part of a longitudinal randomized controlled trial for reducing risk
behaviors among HIV-infected alcohol abusers. Recruitment was made in densely
populated, multicultural, low income, urban areas of Miami-Dade County, Florida.
Participants were between 18 and 60 years of age, HIV-positive and willing to present
documentation to confirm serostatus, consumed alcohol within the last 3 months, with a
history of alcohol abuse or dependence within the past 2 years, and, at the time of
recruitment, were not showing overt signs of major psychiatric disorders. Additionally,
availability to provide blood specimen was required. All participants provided signed
informed consent as approved by the Institutional Review Board (IRB) at Florida
International University.
Participants were evaluated for alcohol use by the Timeline Followback (TLFB)
and the Alcohol Use Disorders Identification Test (AUDIT) test. All participants were
assessed using the same battery of neurocognitive tests and in the same order. Nonverbal
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memory was measured with the RCFT. Cognitive flexibility and sustained visual
attention was measured with the CTT test A & B, and executive function was measured
with the SCT.
2. Genotyping
DNA was extracted from whole blood by manual extraction using the QIAamp
DNA Mini Kit (Valencia, CA). SNPs rs6277 and rs1800497 were genotyped using the
TaqMan® SNP Genotyping Assays (Foster City, CA). Allelic discrimination analysis
was performed on the Bio-Rad CFX96™ real-time PCR machine (Hercules CA).
For VNTR D4, Bio-Rad CFX Manager software (version 3.0) was used for data
acquisition and genotype assignment. The primer sequences used for the D4
amplification were obtained from a previous study.29 The sequence was as follows:
5'CTGCTGCTCTACTGGGC 3' sense and 5'GTGCACCACGAAGGAAGG 3' antisense
The 25 μl reaction mixture contained: 1 x PCR amplification buffer (Qiagen, Valencia,
CA), 300 μM dNTPs, 0.5 μM of each primer, 0.5 U Taq DNA polymerase (Qiagen) and
50ng of genomic DNA. The temperature cycle consisted of an initial denaturation at 94
ᴼC for 5 min, followed by 30 cycles of annealing for 40 s at 54 ᴼC, extension for 40 s at
72 ᴼC, denaturing for 40s at 94ᴼC, and then the final extension for 6 min at 72 ᴼC. The
amplification products were separated on a 3% agarose gel electrophoresis according to
the number of repeats. The size of the amplified fragments was from 500 bp to 750 bp (27 copies of the 48pb repeat). These genetic markers were chosen based on prior evidence
of the SNPs conferring risk to neurocognitive deficits or a theoretical association with
executive function.
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3. Neurocognitive measures
The neurocognitive test battery included standardized measures of multiple domains of
cognitive function selected for their sensitivity to HIV-associated neurocognitive
impairment. The neurocognitive tests were assessed in the following domains:
1.

Visual Memory-Rey-Osterrieth Complex Figure Test evaluated
visuospatial construction and nonverbal memory.30 It consists of a
complex geometric figure that is copied and then redrawn from memory.31
Copy and accuracy of correctly copied or recalled elements was measured
based on a score from 0 to 36. The figure was divided into 18 components.
Each piece was evaluated with respect to its drawing accuracy with higher
scores indicating better accuracy. High test-retest reliability scores 0.88
for copy and 0.87 for recall 31

2.

Sustained attention- Color Trail Test part A evaluated sustained
attention.32 Trail A required the individual to connect colored circles
numbered 1-25 as fast as possible using a pencil. All odd-numbered circles
had a pink background, while all even-numbered circles had a yellow
background.33 The test measured time in seconds to complete with higher
scores indicating poor performance. High test-retest reliability, scores
ranging from 0.85 to1.00.32

3.

Cognitive flexibility- Color Trail Test part B evaluated cognitive
flexibility. Participants were presented with numbered colored circles that
required to start with a pink colored number one circle and alternate
between pink and yellow colored circles as fast as possible.32 The test
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measured time in seconds to complete with higher scores indicating poor
performance. High test-retest reliability scores ranging from 0.85 to
1.00.32
4.

Executive function-The Short Category Test evaluated executive function.
It consisted of five booklets with 20 cards per subtest and required the
individual to formulate an organizing concept for each subtest.34 The
number of errors on each booklet was added and the total number of errors
determined impairment with lower scores representing better executive
function.35 Test-retest coefficients range from 0.60 to 0.96 depending upon
the severity of impairment in the sample.34

The neurocognitive tests were completed at baseline. Trained personnel administered the
tests in the same order and according to standardized procedures.
4. Alcohol Use
The TLFB method assessed alcohol use and other drugs of abuse. This method
obtains estimates of substance use by using a calendar format and providing retrospective
estimates of the participant's substance use over the last three months.36 The AUDIT is a
screening tool that is sensitive to early detection of high-risk drinking behaviors as shown
in Table 1.37
D. Analysis
Since 112 (29%) individuals chose not to participate in this study, data were
evaluated for potential selection bias. Statistical analyses were performed using Stata
v.11 (StataCorp, College Station, TX). Logistic regression and linear regression analyses
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were used to explore the association between dopamine-related genes and cognitive
impairment (executive functioning, cognitive flexibility and visual memory). The
statistical threshold was set at P < 0.05 and 95% confidence intervals (CIs). Ethnic and
gender -specific associations were calculated through stratified analyses. Genotyping
counts were tested for HWE for each SNP. For the DRD4 polymorphism, the Pearson's
X2 and t-test were used to compare group differences. For DRD4 48 bp VNTR, alleles
were grouped in short (S; < 7 repeat) and long (L; ≥ 7 repeat) as described in previous
studies.38, 39 For statistical analysis, participants were placed in one of two genotype
groups 7-allele present (homozygous for the short allele) or 7-allele absent (heterozygous
or homozygous for the long allele).
To standardize cognitive measures for this study, standardized T-scores were
developed by using multiple linear regression methods analyzing the influence of age,
sex, education, and ethnicity on each cognitive test score. Each of the cognitive domains
was included as dependent variables. The continuous predictor was age, and the
categorical predictors were sex, education and race/ethnicity. For each regression, all the
predictors were included in the model, retaining only the variables that significantly
contributed to the prediction of cognitive test score. The β weights of each of these
predictors in the final model, as well as the standard error of each regression model, were
used to calculate predicted scores on each test. These predictive scores were subtracted
from each individual actual composite score to calculate residual scores. Residual scores
were then converted to T-scores (mean = 50; SD = 10). T-scores were used to determine
cognitive impairment according to the Frascati criteria.40 For the cognitive domains,
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scores were developed as follows: executive function (SCT), visual memory (RCFT)
sustained attention (CTT A) and cognitive flexibility (CTT B).
E. Results
Of the 379 participants recruited for the main study, 70% (N = 267) provided
blood samples. The participants were 94 (34%) females and 173 (65%) males. The
average age in the sample was: (males: mean = 45.1 SD = 7.1; females: mean = 45.3 SD
= 65.9). The majority of participants self-identified as African-American 203 (76%),
followed by Hispanic 43(16%) and Caucasian 21 (8%). A total of 190 (69%) had
completed high school. At baseline, participants provided recent (within one month from
intake) lab tests of CD4 count and viral load. Lab reports showed viral load as
undetectable for 128 (48%) of the sample and an average CD4 count of 440 cells/mm3
(SD = 287). The overwhelming majority of participants, 219 (81%) reported currently
taking antiretroviral medication. Selection bias was not observed when participants’
characteristics in the main study were compared to those in the present study. Results
demonstrated that the participants were similar in age, education, sex, ethnicity and HIV
clinical characteristics as shown in Table 2.
1. Alcohol and other drugs of abuse
The TLFB determined alcohol and other drugs use. Questions included a total
number of standard drinks consumed in the last 90 days, the total number of heavy
drinking days (< 5standard drinks) in the last 90 days, and lifetime alcohol use. A
standard drink is defined as 12 oz of beer, 5 oz of wine, 1.5 oz of liquor all of which
contain approximately 13.6 g of absolute alcohol.41 Results showed a mean AUDIT score
of 16, which is categorized as a harmful drinking level. In addition, a total of 101 (38%)
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of the participants scored > 20 which is indicative of possible alcohol dependence.
Lifetime alcohol use averaged 23.8 years for this sample. Additional detailed information
on other substance use was also assessed. The main drugs used, besides alcohol, were
cocaine and marijuana, with an average use in the last 90 days of 33 and 25 times,
respectively.
The Frascati criteria were used to measure asymptomatic neurocognitive
impairment, (1 standard deviation below the mean in at least 2 cognitive domains).
Results for the neurocognitive measures were below average (T-score: mean = 50 SD =
10) with the exception of sustained attention (mean = 56.0, SD = 9.8). The cognitive
domains with the lowest average scores were cognitive flexibility (mean = 45.7; SD =
10.8) and executive function, with the lowest scores representing better cognition (mean
= 58.2; SD = 10.9).
2. DRD2 polymorphism and cognitive flexibility
Results of the analyses are presented in Tables 3 and 4. All SNPs were in HardyWeinberg equilibrium. The SNP rs6277 of DRD2 gene showed an overall association
with impaired cognitive flexibility (odds ratio = 1.7, 95% CI, 1.3-2.6; p = .01) and with
executive function (odds ratio = 3.6, 95% CI, 2.4-8.7; p = .001). The association between
SNP rs1800497 and cognitive flexibility was non-significant. Results were stratified by
sex and race for cognitive flexibility and executive function. Testing show an increased
risk for executive function impairment in African Americans (odds ratio = 3.1, 95% CI,
2.3-3.5; p = .001), and an even greater risk for males (odds ratio = 3.5, 95% CI, 1.5-5.5; p
= .008). There was, a significant gender interaction for cognitive flexibility (pinteraction =
0.013 for sex), but not for executive function (pinteraction = .35 for sex). Interaction with
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alcohol was not significant (p = .32) and no significant gene-gene interactions for DRD4
and DRD2 were found (results not shown).
3. DRD4 48bp VNTR polymorphism and executive function
The allele frequencies for DRD4 48bp VNTR were similar to those observed in
African populations in other studies.42, 43 In this study, the most frequently detected
alleles of the 48bp VNTR of the D4 receptor were for DRD4-allele 4 (353/484, 72.9%),
and DRD4-allele 7 (66/484, 13.7%). To a lesser degree DRD4-allele 2 (38/484, 7.8%),
DRD4-allele 3 (7/484, 1.5%), DRD4-allele 5 (11/484, 2.3%), and DRD4-allele 6 (9/484,
1.8%) were also present. The nine and ten repeat alleles were not detected in this study
population. The genotype distribution of the 242 participants is shown in Table 5. One
hundred and eighty-six participants were grouped into the 7-absent allele group (< 7
repeats), and 56 were grouped into the 7-present allele group (≥7 repeats). When
comparing allele groups, the 7-allele present and 7-allele absent groups did not differ in
sex, race/ethnicity, alcohol use, or CD4 count. The 7-absent allele group mean score was
associated with a higher rate of error in SCT measuring executive function than the 7present group (mean: 0.17, 95% CI 1.17-1.29; p = 0.008). In addition, a multiple linear
regression with executive function as the dependent variable and age, sex, alcohol use,
genotype group and race/ethnicity as the independent variables showed that DRD4 7absent allele and age had a significant effect on executive function. Whereas, sex, alcohol
use and race/ethnicity did not show a significant effect (data not shown).
F. Discussion
This study provided evidence that suggests genetically determined differences in
DRD2 gene polymorphism (rs6277) and in the DRD4 gene (48 VNTR) are associated
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with impaired executive function and cognitive flexibility. However, no associations
were found with SNP rs1800497. It is well-recognized that genes are likely to affect more
than one cognitive function, and variations in cognitive functions are likely to be
influenced by more than one gene.44 Similarly, this study showed that the DRD2, SNP
rs6277 is associated with impairment in two cognitive domains: executive function and
cognitive flexibility. Conversely, executive function is influenced by DRD2 and DRD4
genetic polymorphisms. Although recent publications stress the need to consider genegene interactions, our results showed no such interactions.44
The present study found a significant association between DRD2 genetic
polymorphisms and executive dysfunction and impaired cognitive flexibility. The study
showed that SNP rs6277 CC homozygous genotype was less efficient in inhibitory
control as it took them more time to complete the task than TT and CT genotypes.
Results of this study are consistent with those that reported an association between CC
genotype and poorer working memory performance and executive functioning.45, 46,32
However, results are mixed in the literature regarding the precise influence of the
SNP rs6277 DRD2 on distinct cognitive processes and the effect's direction
respectively.47 For example, one study showed that high circulate DRD2 binding
potential in the TT genotype was associated with a higher rate of error in the Wisconsin
Card Sorting Test, measuring executive function.48 Conversely, Colzato and colleagues
reported lower inhibitory control in SNP rs6277 CC homozygous genotype, which was
associated with lower levels of DRD2 striatal dopamine availability.49 This incongruence
may be explained by a recent analysis on the regional specificity of SNP rs6277 in the
DRD2 gene.50 The DRD2 genotypes lead to differences in binding affinities and
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availabilities in striatal versus extrastriatal regions.50 In all extrastriatal regions the CC
genotype is associated with the highest DRD2 binding potential, whereas the CC
genotype is associated with the lowest binding potential in the striatum.51 Thus, the SNP
rs6277 in the DRD2 gene changes the receptor's affinity and regulates DRD2 availability,
but its effect differs depending on the brain region under investigation.50, 51 Neuroimaging
studies suggest that the functional SNP rs6277 is associated with DRD2 density changes
across the cortex and thalamus.50 For example, a meta-analysis showed a significant
association between the SNP rs6277, C allele and schizophrenia.52 Furthermore, studies
have proposed that higher cortical DRD2 density is a risk factor for executive dysfunction
as shown for schizophrenia.19, 53, 54 Thus, our results suggest that higher cortical DRD2
density may also be considered a risk factor for HIV-associated neurocognitive
impairment.
The DRD4 48bp VNTR polymorphism has been previously linked to ADHD
phenotypes.28, 55-58 In particular, the specific allele (7-repeat) of the 48pb VNTR
polymorphism in the coding region of DRD4 may be a risk factor for the development of
ADHD.28 ADHD is known to alter prefrontal cognitive functions that are often related to
dopaminergic dysfunction. 59 Thus, following previous studies on ADHD, this study
sought to assess whether cognitive functions (cognitive flexibility and executive function)
were associated with the DRD4 48bp VNTR polymorphism in HIV-infected adults.
Results in this study showed that the 7- absent allele group was significantly associated
with executive dysfunction. The effect of the DRD4 VNTR on executive function
reported herein is comparable with a familial study that reported a significant association
between the 7-absent allele group and lower scores in working memory and executive
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function.55 Similarly, several studies on DRD4 VNTR showed that DRD4 7-absent allele
group was associated with worse cognitive functioning than the DRD4 7-present allele
group.57, 60 However, the results of this study conflicts with the findings of other similar
studies. One study found poorer inhibitory performance in the 7-present allele group
versus the 7-absent allele group.56 Another, found that 7-present allele group performed
better that the 7-absent allele group on verbal memory, but for visuo-constructive ability
(WAIS-III Block Design ) and set shifting (WCST) the 7-absent allele group performed
better than the 7-present allele group.61
This poses important questions with respect to the relationship between genetic
risk and neurocognitive performance. There are several potential explanations for these
conflicting results. First, higher and lower than average levels of synaptic dopamine may
lead to neurocognitive impairment.62 This is a particularly interesting since the 7-present
allele is associated with reduced receptor functioning.61 Second, the combinations of
certain risk genotypes rather than one single risk genotype may lead to the presence of
cognitive dysfunction.63 Third, Boontra and colleagues suggested that the investigation of
haplotypes rather than genotypes may yield stronger associations.61 These relationships
have not been fully tested and required further research, especially since cognitive
endophenotypes are important for HIV-associated neurocognitive impairments.
Due to the exploratory nature of the study, multiple statistical comparisons were
made. Because of the low power of the study to detect smaller effect sizes, some
important associations may not have emerged as statistical significant. These results
should be viewed with caution and should be replicated before definitive conclusion can
be drawn. Alternatively, these results can serve as an initial point for future research in
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cognitive phenotypes for HAND in adults. Molecular genetics, as applied in the present
study, offers further analytic insight of the analysis besides behavioral assessment and
neuroimaging, and may present a reasonable instrument for the dissociation of different
executive control processes. Since most of the polymorphisms have a relative small effect
on cognition, to detect an effect, a larger sample is optimal. In addition to the genes
analyzed in this study, other genes related to cognitive function should be included in the
future.
In summary, the present study provides evidence that genetically determined
differences in the SNP rs6277 DRD2 gene and DRD4 48bp VNTR may be a risk factors
for executive function and cognitive flexibility deficits. Furthermore, rs6277 showed an
association with impairment in two cognitive domains (executive function and cognitive
flexibility) while executive function seems to be influenced by DRD2 and DRD4 genetic
polymorphisms. Finally, DRD4 48bp VNTR (7-allele absent group) was associated with
executive dysfunction, which is in line with the recent proposal that either higher or
lower levels of synaptic dopamine may lead to neurocognitive impairment.
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Table 1. Alcohol Use Disorders Identification Test (AUDIT) scores
Significance of Scores
0 -7

Low risk of alcohol-related harm

8-10

High risk of experiencing alcohol-related harm

11-19

Already experiencing significant alcohol-related harm

20+

Possible alcohol dependent advisable further testing to
determine dependence.
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Table 2. Demographic and clinical characteristics of main study and current study
participants
Demographic Characteristics
Age, mean (DS)
Sex, No (%)
Male
Female
Education No (%)
8th grade or less
High school diploma
Some college
Race/Ethnicity No (%)
Caucasian
African-American
Hispanic
Alcohol use, mean (DS)
Number of standard drinks
(past 90 days)
Lifetime
AUDIT score
Other drugs, mean (DS)
Number of times cocaine use
(past 90 days)
Number of times marijuana use
(past 90 days)
HIV Characteristics, mean (DS)
CD4 count
Viral load No (%)
undetectable
50-10,000
10,001 - 30,000
30,000 or more
Taking ART
Cognitive measures, mean (DS)
Executive skills T-scores
Memory skills (learning) T-scores
Memory skills (recall) T-scores
Cognitive flexibility T-scores
Sustained attention T-scores
Visual Memory T-scores

Main study

Current study

n = 112

N = 267

44.1 (7.7)

45.1(7.1)

67 (60)
45 (40)

173 (65)
94 (34)

13 (12)
73 (65)
26 (23)

19 (7)
190 (69)
57 (24)

P values
.66
.72
.24

.26
17 (15)
80 (72)
15 (13)

21 (8)
203 (76)
43 (16)

100 (50.1)

190 (100.1)

.10

22 (10.5)
14 (7.5)

23.8 (10.9)
16 (8.0)

.24
.09

23.5 (16.8)

33.5 (19.8)

.25

19.3 (12.5)

25.6 (20.9)

.63

412.9 (318.4)

441.4 (286.9)

.73
.16

45 (40)
39 (35)
8 (7)
20 (18)
76 (68)

128 (48)
80 (30)
29 (11)
29 (11)
216 (81)

.84

50.1 (9.0)
45.9 (10.1)
48.1 (9.8)
40.4 (10.4)
53.9 (9.3)
47.9 (11.9)

48.2 (10.9)
48.2 (9.1)
40.0 (10.5)
45.7 (10.8)
56.0 (9.8)
43.1 (13.8)

.93
.18
.11
.09
.10
.09
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Table 3. DRD2 and ANKK1 associations with cognitive domains
Chr.

Positiona

Gene

Variant

Allelesb

Domain

OR (CI%)

11

11:113412737

DRD2

rs6277

C/T

Cognitive
flexibility

1.7 (1.3 to 2.6)
p = .01

11

11:113412737

DRD2

rs6277

C/T

Executive
function

3.6 (2.4 to 8.7)
p = .001

11

11:113400106

ANKK1

rs1800497

C/T

Cognitive
flexibility

1.1 (0.7 to 1.8)
p = .71

Table 4. DRD2 associations with cognitive flexibility and executive function
by gender, race/ethnicity groups and alcohol use (ORs and 95% CIs)

DRD2 rs6277
(executive
function)

Females

Males

1.3

3.5
(1.5 to 5.5)
p = .008

pinteraction = .35
DRD2 rs6277
(cognitive
flexibility)

0.9

Hispanics

African
American

2.6

3.1
(2.3 to 3.5)
p = .01

Alcohol Use
2.6

pinteraction = .05

1.8
(1.2 to 2.9)
p =.01

1.9

pinteraction = .013

1.5

pinteraction =.72
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1.6
(1.4 to 2.4)
p =.03
pinteraction = .32

Table 5. D4 Receptor 48bp repeat genotype group classification
D4 receptor 48bp
repeat genotype

N

%

Genotype
group

2/2

8

3.3

1

2/3

2

0.8

1

2/4

20

8.4

1

3/4

2

0.8

1

3/6

3

1.0

1

4/4

140

57.8

1

4/5

5

2.0

1

4/6

6

2.6

1

4/7

40

16.7

2

5/7

6

2.4

2

7/7

10

4.2

2

Group 1: 7-absent group: < 7-fold repeat of the 48bp repeat of D4 receptor
Group 2: 7-present group: ≥ 7-fold repeat of the 48bp repeat of D4 receptor
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CHAPTER V
A RANDOMIZED CONTROL TRIAL OF A MANUAL-GUIDED RISK REDUCTION
INTERVENTION FOR HIV-INFECTED ALCOHOL ABUSING INDIVIDUALS
A. Abstract
Improved HIV treatments and decreased mortality from AIDS-related illness have
been paralleled by increased prevalence of HIV infection. HIV infection transmission
risk is compounded by alcohol abuse and related risky sexual behaviors. Interventions
that target alcohol use are central to improving the health of HIV-infected alcohol
abusers. This study randomized 284 HIV-infected alcohol abusers to either the adapted
Holistic Health Recovery Program (HHRP-A) or the Health Promotion Comparison
program (HPC). Overall HIV sexual transmission risk behaviors decreased in both the
experimental HHRP-A and HPC control groups. Cognitive impairment was measured as
a moderator for alcohol use. Results showed that impaired cognitive flexibility and visual
memory were associated with increased alcohol use. (F = 1, 3.82, η2 = 0.03, p = .05;, and
F = 1, 5.79, η2 = .05 p = .02) respectively. At the six-month follow-up, HHRP-A
participants were less likely to report trading sex for food, drugs and money (20.0%) and
unprotected insertive or receptive oral (11.6%) or vaginal and/or anal sex (3.2%) than
HPC participants (49.4%, p <.001; 22.5%, p=.05; 15.4%, p=.04). The number of times
that sex was traded for food, money and drugs decreased in men in the HHRP-A
experimental group (food: Z = 2.2 p = .03; money: Z 3.4 p = .001; drugs: Z = 3.1 p
=.002). Similarly, men and women exhibited decreases in the number of episodes of sex
following alcohol consumption (men: Z = 2.0 p = .04; women: Z = 2.3 p = .02). This
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study suggests that HHRP-A is an effective intervention program for the reduction of
sexual transmission risk behaviors in HIV-infected alcohol abusers.
B. Introduction
The reduction of HIV transmission risk behaviors among HIV-infected
individuals remains a major health priority. Depression, substance use, and stressful,
traumatic experiences have been identified as predictors of sexual transmission risk.1, 2
The impact of heavy alcohol use in HIV-infected individuals has not been extensively
examined.3, 4 Approximately 5% of the total US population abuses alcohol. However, the
prevalence of alcohol abuse in HIV-infected individuals is between 30 to 60%.5, 6 HIVinfected alcohol abusers are more prone to rapidly progressing illness with higher viral
loads, increased immune suppression, and cognitive impairments compared to HIVinfected alcohol non-abusers.3 Behavioral factors associated with alcohol abuse can also
increase HIV disease progression, interfering with antiretroviral therapy adherence.4
Alcohol consumption impairs judgment and cognition which diminishes risk perception,
therefore increasing HIV risk transmission.7 Over 70% of people infected with HIV
remain sexually active after diagnosis and one-third engages in unprotected sexual
behavior.8
An area of recent interest is on the interaction between alcohol and HIV on
cognition. Regular daily consumption of six or seven standard alcoholic drinks may be
associated with moderate cognitive impairment.9 On the other hand, individuals affected
by both alcohol abuse and HIV infection may suffer a compounded deficit in cognitive
performance which may affect adherence to antiretroviral medication and treatment
outcomes.10 Clinical research shows that not all chronic drinkers are equally at risk for
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brain changes; most suffered mild cognitive impairment that improved within a year of
abstinence.11, 12
A study reported high rates of knowledge on how to prevent HIV transmission
among infected persons, but uncertainty about how to make these changes was a factor
for not changing their behavior.13 Efforts to reduce risk of HIV transmission and alcohol
abuse have been guided by several models of health behavior change.14 One theoretical
approach that has effectively predicted HIV-related health behaviors in diverse samples is
the Information-Motivation-Behavioral Skills (IMB) model.15, 16 The model states that
HIV prevention information and motivation work through preventive behavioral skills to
influence risk reduction behaviors.17 The Holistic Health Recovery Program (HHRP) is
an evidence-based intervention guided by the IMB model for HIV-infected drug users.18
The HHRP-A is an adapted version of the HHRP program designed for alcohol abusers
based on the IMB model. The HHRP-A is a manual-guided intervention designed to
reduce sexual transmission risk and alcohol use in HIV-infected alcohol abusers.19 In
addition, the HHRP-A incorporated cognitive remediation strategies by using materials
and techniques that minimize the effects of cognitive difficulties. This study evaluated
the effectiveness of the IMB-based, manual-guided intervention using HHRP-A to reduce
sexual transmission risk and alcohol use in HIV-infected alcohol abusers.
C. Methods
1. Sample
A total of 284 HIV-infected adults were recruited from CBOs in Miami, Florida,
between January 2009 and November 2012. The slow recruitment process was planned to
help reduce treatment group cross-contamination and group assignment bias. The
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inclusion criteria for the participants were age between 18 and 60 years, HIV-positive and
willing to present documentation to confirm serostatus, alcohol consumption within the
last three months and/or a history of alcohol abuse or dependency within the past two
years, and at least one episode of unprotected vaginal or anal sex in the past 90 days.
Additional criteria included: ability to understand and speak English, understand and
give informed consent, provide contact information for follow-up interviews, willingness
to be randomized to the experimental or control group, not facing immediate
incarceration or residence in a restricted environment, and no evidence of major
psychiatric disorders. The Institutional Review Board of Florida International University
approved the research protocol, and all participants provided signed informed consent
prior to participating in the study.
2. Neurocognitive Assessment
The following tests measured neurocognitive deficits at baseline. 1) The Short
CategoryTest- measured executive function by abstract concept formation and learning,20
2) The Rey-Osterrieth Complex Figure Test-measured visual memory,21 3) The Auditory
Verbal Learning Test-measured retention rates, learning rates and recognition,22, 23 4) The
Color Trail Test part A-measured sustained attention,24 and 5) The Color Trail Test part
B-measured cognitive flexibility.24 The Frascati criteria were used to measure
impairment.25
3. Study Design
This study was a prospective randomized clinical trial where participants were
assigned to the experimental or control groups. Participants were entered into the study in
cohorts of eight of the same gender. Cohorts were assigned to receive either the
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experimental or control condition according to a computer-generated random sequence.
The random sequencing controlled for bias in subject assignments across conditions. The
experimental group used the HHRP-A intervention program designed to promote risk
reduction behaviors among HIV-infected alcohol abusers.26 The HHRP-A intervention
manual was highly structured and involved both didactic presentations of material as well
as experiential exercises. Participants attended eight sessions lasting two hours, twice a
week, for four weeks. The intervention addressed harm reduction skills training, relapse
prevention and reduction in HIV sexual transmission risk behaviors. Each session was
co-facilitated by two counselors using a nonjudgmental, motivational enhancing
therapeutic style. Cognitive remediation strategies were incorporated because of the
potential for cognitive impairment in this population. Some of these strategies included
emphasis on structure and consistency, repetition and review, behavioral games and
memory books, as well as ongoing assessment of new learning and retention, with
immediate provision of feedback.
The Health Promotion Comparison (HPC) group focused on educational and
didactic methodologies, addressing common health problems such as nutrition, physical
fitness, and healthy living. The HPC did not incorporate behavioral skills training or
motivational enhancement techniques. The HPC matched HHRP-A in total
administration time and format (eight, two-hour sessions). However, the program was
condensed and delivered in two days to reduce the risk of cross-group contamination and
the potential for enhancing social support that group sessions repeated over time could
engender. A standard care HIV education component was included in the HPC because it
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was considered ethically irresponsible not to include HIV education in a comparison
condition, given the high-risk nature of this population.
Assessments were conducted at baseline and six-month follow-up. The timeline
follow-back (TLFB) method was used to measure alcohol use and sexual transmission
risk behaviors. TLFB uses a calendar format that provides retrospective estimates of the
participant's substance use and sexual conduct over the last 90 days.27 Alcohol abuse was
defined by the amount consumed (e.g., at risk, heavy) or by the consequence of its use
(e.g., abuse, dependence).4 Alcohol abuse is defined by the National Institute on Alcohol
Abuse and Alcoholism (NIAAA) as > 4 drinks on an occasion or >14 drinks in a week
for men, and > 3 and > 7 for women, respectively.28 In addition, computer assisted
personal interview, and audio computer assisted self-interview were used for baseline
data. Data were collected at baseline and six-month follow-up for all measures.
Participants were offered incentives for participation as follows: $50 gift card to local
stores upon completing the baseline data collection; $25 gift card upon completing postintervention assessments; $15 cash or gift card for attendance at each group session; and
$5 cash for transportation.
4. Outcome Measures
At the baseline and six-month follow-up assessments, participants reported on
alcohol use and sexual transmission risk behaviors. The number of vaginal, anal and oral
sex events without a barrier and times participant traded sex for food, money, or drugs,
and number of sex events directly following alcohol consumption were used to measure
sexual transmission risk. The number of drinking days, heavy drinking days (≥ 5
standard drinks), and the number of standard drinks were used to measure alcohol use.
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Report of any or no incident of trading sex for food, drugs and money, sex directly
following alcohol consumption, unprotected insertive or receptive oral, anal or vaginal
sex were compared as categorical variables at six-month follow-up by group assignment
(HHRP-A versus HPC). Hazard ratios (HRs) were calculated as measures of relative
risk; 95% confidence intervals and p-values from Chi-square or Fisher’s exact 2-tailed
tests were used for significance testing.
Analyses were conducted with SPSS version 20 (IBM, 2011). Continuous
measures were quantities consumed or frequency of alcohol use and sexual transmission
risk events. Data for alcohol use were transformed using the Box-Cox method,29 and
sexual transmission risk used nonparametric methods. Initially, the Wilcoxon signed-rank
test was used for all the analyses. Transformed data were analyzed using the t-test and
ANOVA methods to measure the outcomes. Change over time on continuous measures
was analyzed using two repeated measures by analyses of variance (ANOVAs) for
treatment condition and time variables. Where change over time in any continuous
variable was detected, effect sizes (partial η2) were reported. The intervention outcomes
were assessed by alcohol use measured by total number of standard drinks in the last 90
days and the total number of heavy drinking days (≥ 5 standard drinks) in the last 90
days. Sexual transmission risk was measured by number of insertive and receptive anal or
vaginal sex events without a condom, number of episodes receiving or giving oral sex
without a barrier, number of times the participant traded sex for food, drugs and money,
and number of sex events directly following alcohol consumption. The outcomes were
modeled as a function of condition (intervention or control), time (baseline and followup), gender, and condition by time. The interaction between neurocognitive measures and
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alcohol was also measured in both conditions. Cognitive impairment was measured by
normalized T-scores in this sample. Normalized T-scores were developed by using
multiple linear regression methods analyzing the influence of age, sex, education, and
ethnicity on each cognitive domain. The normalized T-scores (mean = 50 and SD =10)
were used to determine cognitive impairment.
D. Results
A total of 284 participants were randomized to either the control group 140
(49.3%) or the experimental group 144 (50.7%). There was no significant difference
between the groups in age, or gender (Table 1). The predominant race for both groups
was African American (control group: 71%; the experimental group: 72%). They did not
differ significantly by ART use and immunologic or virologic status. Demographic,
behavioral and clinical characteristics for the control and experimental groups are
presented in Table 1. According to Frascati criteria a total of 109 (41%) of the
participants in the sample scored below the mean, in the domains of executive function,
cognitive flexibility and memory (T-score: mean = 50; SD =10). Asymptomatic
neurocognitive impairment, greater than one standard deviation below the mean was
observed in 98 (90%) of these individuals, and mild neurocognitive impairment, greater
than two standard deviations below the mean was observed in 11 (10%). (Frascati
definition Table 3, Chapter 2). The proportion with neurocognitive impairment at
baseline did not differ significantly between the two groups.
1. Alcohol use
Analyses of the intervention impact on the outcomes for alcohol consumption
revealed an overall significant decrease in alcohol consumption by time (F = 3, 162, η2 =
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0.54, P = <.01) for the experimental and the control groups, but there were no significant
differences between experimental and control groups in alcohol use reduction. When
cognitive impairment was measured as a moderator for alcohol use. Results showed that
impaired cognitive flexibility and visual memory were associated with increased alcohol
use. (F = 1, 3.82, η2 = 0.03, p = .05; and F = 1, 5.79, η2 = .05 p = .02), respectively.
2. Sexual transmission risk
Proportions of study participants who reported HIV risk behaviors at six-month
follow-up differed by intervention group assignment; in all cases, participants in the
experimental condition had better risk reduction outcomes. At baseline trading sex for
food, drugs or money and number of sex events directly following alcohol consumption
were the most frequent HIV risk behaviors reported. At the six-month follow-up, HHRPA participants were less likely to report trading sex for food, drugs and money (20.0%)
and unprotected insertive or receptive oral (11.6%) or vaginal and/or anal sex (3.2%) than
HPC participants (49.4%, p <.001; 22.5%, p=.05; 15.4%, p=.04) shown in Table 2.
Additionally, a significant decrease for trading sex for food, money and drugs (food: Z =
2.2 p = .03; money: Z 3.4 p = .001; and drugs: Z = 3.1 p = .002), as well as decreased
number for vaginal sex events without a barrier (Z = 1.9 p = .05) was observed over time
in study participation, which was statistically significant only in men. Both men and
women had similar statistically significant decreases in number of reported sex events
directly following alcohol consumption (men: Z = 2.0 p = .04; women: Z = 2.3 p = .02).
No significant changes for number of anal or oral sex events without a barrier were
reported. The control group showed a small decrease in trading sex for food, money or
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drugs, sex following alcohol consumption. However, this decrease was not significant as
shown in Table 3.
3. Attrition analysis
Of the 278 participants who completed the baseline assessment, 185 (66%) also
completed the six-month follow-up assessment. Of the 94 (34%) participants who did not
complete the follow-up assessment, three died, one went to jail, and 90 were excluded
from the analyses due to incomplete data and/or were lost to follow-up. Some of the
reasons for loss to follow-up included seeking health care at another clinic and not
returning to complete the assessment for unknown reasons. No difference (p > .35) in
attrition was seen by study condition, demographic factors, or baseline sexual
transmission risk behaviors (vaginal, anal and oral sex without a barrier, trading sex for
food, money, or drugs, and number of sexual events after alcohol use) or for alcohol use
(total number of standard drinks in the last 90 days and total number of heavy drinking
days in the last 90 days).
E. Discussion
The study evaluated the efficacy of the HHRP-A intervention program and
showed a significantly lower level of HIV transmission risk behaviors at the six-month
follow-up assessment in the experimental compared to the control group. Proportions
reporting sexual transmission risk behaviors including trading sex for food, money, or
drugs and unprotected sex were 49% to 80% lower six months post-intervention among
HHRP-A participants versus comparison group members. Additionally, alcohol use
decreased for number of heavy drinking days (≥ 5 standard drinks) and total number of
standard drinks in both the intervention and control groups.
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Alcohol abuse has been associated with increased involvement in sexual risk
behaviors, including sex under the influence, trading sex for drugs or money, and vaginal
and/or anal sex events.30 Very few HIV intervention programs address alcohol abuse as
part of their intervention; our results are encouraging in that respect.31-34 In addition, a
significant interaction effect was found between alcohol use and cognitive impairment in
the domains of cognitive flexibility and visual memory which were associated with
increased alcohol use. These results are similar to clinical studies showing that alcohol
abuse is associated with impairments in specific neuropsychological functions.12
However, some studies have suggested an increase in vulnerability to cognitive
impairment due to the interaction between chronic alcohol use and HIV infection.35, 36
For example, one study examined the effect of current heavy alcohol use and HIV
infection on cognitive performance and found a synergistic effect for the heaviest current
drinkers (> 6 drinks per occasion) and HIV infection on motor and visuomotor speed.37
Individuals affected by both alcohol dependency and HIV infection may suffer
compounded deficit in cognitive performance which may affect ART adherence and
treatment outcomes.10 The results in this study showed a similar trend of lower
functioning in cognitive areas affected by both alcohol and HIV infection.
Alcohol use may not only interfere with prevention strategies, but may threaten
the success of emerging biomedical approaches to HIV prevention.4, 38, 39 Behavioral
interventions such as HHRP-A specifically tailored for HIV-infected alcohol abusers are
necessary for this population. To our knowledge this is the first HIV intervention study
that demonstrated specific reductions in sexual transmission risk behaviors in HIVinfected alcohol abusers. The current study also provided important information about
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which sexual transmission risk behaviors are most common among HIV-positive alcohol
abusers. These behaviors include trading sex for money and drugs, unprotected sex, and
sex following alcohol use. These preliminary results showed that HHRP-A is an effective
intervention for sexual transmission risk-reduction behaviors. However, the highest
decrease in sexual risk behaviors were observed mostly in men. These results may be
related to the women's economic dependency on men, as well as to the men's
cooperation in decreasing sexual risk behaviors. Thus, it is important to incorporate risk
reduction behavior strategies that are specifically geared for men and women
respectively.
There were a few limitations in the ability to draw conclusions in this study. First,
for ethical reasons, the participants who were active in alcohol or drug abuse treatment
programs could not be excluded. Thus, we were not able to determine the extent to which
HHRP-A components alone had an impact on alcohol use at the six-month follow-up.
This is an important issue that should be addressed in the future. Second, although
significant differences were found for sexual transmission risk behaviors the high loss to
follow up (34%) limits the interpretability of the findings. Last, alcohol use and sexual
transmission risk were assessed by self-reports alone allowing for either overestimation
or underestimation of the number of sexual events or quantity of alcohol consumed.
Some of the strengths in this study were the ethnic diversity of the sample and the
representation of patients with neurocognitive impairment. Second, the HHRP-A
program covered a range of topics relevant to HIV-infected alcohol abusers and provided
cognitive remediation strategies to facilitate learning and retention. Moreover, the
treatment condition was manual-guided, and procedures for assuring the integrity of the
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treatment conditions were used. Finally, this population was recruited from Miami-Dade
County, Florida, the metropolitan area with the highest HIV prevalence in the nation: our
results may be relevant for other highly-impacted urban areas.40
In conclusion, findings from this study, although preliminary, suggest that
enhancing substance abuse treatment with comprehensive interventions that address the
special needs of HIV-infected alcohol abusers can provide important benefits.
Implementation of interventions, such as HHRP-A that target individuals already infected
with HIV appear to be essential to control the spread of HIV. These interventions will
need to meet the special needs of substance-using HIV-infected population and should be
incorporated into addiction treatment.
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Table 1. Baseline Demographic, behavioral and clinical characteristics of the control and
experimental groups
Characteristics
Age in years, mean (SD)*
Male

Control
n = 140 (%)

Experimental
n = 144 (%)

P value

44.9 (7.5)

45.4 (6.8)

.70

77 (55)

89 (62)

.67
.43

Ethnic background
Caucasian

13 (9)

20 (14)

African American

99 (71)

104 (72)

Hispanic

19 (14)

23 (16)
.44

Education
Some college

29 (21)

37 (26)

High school diploma

53 (38)

48 (33)

Some school no diploma

58 (41)

59 (41)

469 (303.8)

466 (328.9)

.42

Viral load undetectable

60 (43)

76 (53)

.56

Taking antiretroviral therapy (ART)

100 (71)

114 (79)

.24

23.5 (11.2)

23.2 (10.8)

.88

84 (60)

97 (67)

.15

50 (40)

47 (33)

.09

HIV characteristics Mean (SD*)
CD4+ T-lymphocyte count

Alcohol Use and Sex Behaviors
Mena (SD*)
Lifetime alcohol use years
Currently in an alcohol treatment
facility
In the last 12 months in an alcohol
treatment facility
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Table 1. Continued…….

Control group
n = 140

Experimental
group n = 144

P value

Traded sex for food, drugs or money in
last 90 days

59/130 (45.3)

54/149 (36.2)

.12

Had any sexual event directly following
alcohol consumption in last 90 days

69/117 (59.0)

106/143 (74.1)

37/132 (28.0)

48/144 (33.3)

.34

25/132 (18.9)

29/144 (20.1)

.80

Executive function T-scores

50.1 (10.4)

44.7 (10.1)

.001

Cognitive Flexibility T-scores

46.5 (10.5)

43.2 (10.9)

.36

Sustained attention T-scores

45.5 (10.8)

41.1 (10.2)

.29

Visual memory T-scores

50.5 (10.3)

51.1 (10.3)

.44

Memory T-scores

39.6 (9.1)

Characteristics

Had insertive or receptive oral sex
without a barrier in last 90 days
Had vaginal and/or anal sex without a
barrier in last 90 days

.009

Cognitive measures, Mean T scores
(SD*)

Proportion with Neurocognitive
Impairment

49/133 (35%)

*SD standard deviation
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39.8 (10.5)
60/134 (41%)

.46
.19

Table 2. HIV risk behaviors at six-month follow-up by assignment
All
HIV Risk Behaviors
Traded sex for food, drugs and
money, last 90 days

Sex events directly following
alcohol consumption, last 90
days

Insertive or receptive oral sex
without a barrier, last 90 days

Vaginal and anal sex without a
barrier in last 90 days

Number (%)
Reporting
Behavior

Hazard Ratio
(95%CI)*

Experimental

19/95 (20.0)

0.41
(0.27 to 0.64)

<.001

Control

42/85 (49.4)

Experimental

15/106 (14.1)

0.89
(0.43 to 1.8)

.75

Control

11/ 69 (15.9)

Experimental

11/95 (11.6)

0.51
(0.26 to 1.0)

.05

Control

18/80 (22.5)
0.2
(0.06 to 0.70)

.04

Group

Experimental
Control

3/95 (3.2)
12/78 (15.4)

*95%CI 95% Confidence Interval
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P value

Table 3 HIV risk behaviors at six-month follow-up by assignment and gender
Measure
*Traded sex for shelter or food
last 90 days
*Traded sex for money last 90
days

Traded sex for drugs last 90 days

Sex events directly following
alcohol consumption last 90 days
Vaginal sex without a barrier last
90 days
Sex events without a barrier last
90 days

Intervention

Women

Experimental

Z = 1.2 p = .24

Control

Z = 0.7 p = .45

Experimental

Z = 1.2 p = .21

Men

Control

Z = 2.2 p = .03

r = 0.31

Z = 3.4 p = .001

r = 0.35

Z = 0.6 p =.56

Experimental

Z = 0.9 p = .36

Z = 3.1 p = .002

Control

Z = 0.5 p = .62

Z = 0.9 p = .34

Experimental

Z = 2.3 p = .02

Control

Z = 0.9 p = .32

Z = 1.3 p = .20

Experimental

Z = 0.9 p = .32

Z = 1.9 p = .05

Control

Z = 1.5

Z = 0.5 p = .61

Experimental

Z = 1.5 p = .13

Z = 2.7 p = .008

r = 0.37

Control

Z = 0.7 p = .49

Z = 2.2 p = .02

r = 0.27

p = .07

r= 0.30

Z = 2.0 p = .04

r = 0.25

r = 0.34

r = 0.29

The effect size was calculated by dividing the Z by the square root of N (r= Z/√N) using the Wilcoxon Signed-rank Test.
*Measures for trade sex for food or money in the control group were not calculated because of the low number of participants.

108

CHAPTER VI

CONCLUSION
A. Summary of Conclusions
HIV-infected individuals continue to experience neurocognitive deterioration
despite viral suppression due to successful ART treatment.1 Currently, demographic
characteristics, and medical comorbidities are used to identify individuals who are at risk
for HAND.2, 3 However, additional risk factors such as the role of genetics in relation to
HIV-neurocognitive susceptibility should be investigated.4 Memory deficits, and
executive dysfunction are highly prevalent among HIV-infected adults. These conditions
can affect their quality of life, antiretroviral adherence, and HIV risk behaviors.5, 6
Cognitive functions are influenced by the serotonin and dopamine systems. Thus, genetic
differences in the serotonin and dopamine system genes may exacerbate the development
of neurocognitive impairment in an individual.1, 5, 7, 8 The study's overarching hypothesis
was to determine whether specific genetic differences in HIV-infected alcohol abusers
were correlated with executive dysfunction, impaired cognitive flexibility and memory,
and whether these cognitive deficits moderated alcohol use and sexual transmission risk
behaviors.
The third chapter investigated the potential associations between single nucleotide
polymorphisms in the serotonin system genes and cognitive impairment in HIV-infected
adults. A total of 267 biologically unrelated individuals were genotyped for
polymorphisms SLC6A4 5-HTTLPR, TPH2 rs4570625 and GALM rs6741892. The SCT,
CTT A&B and AVLT tests were used to assess cognitive functions. Results showed a
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significant association for TPH2 and GALM variants with executive function and
memory. This study provided further evidence for the role of serotonin in cognition,
where TPH2 and GALM gene polymorphisms affect 5-HT signaling pathway influencing
executive function and memory. These findings parallel and extend those of functional
imaging studies and molecular genetics suggesting that the TPH2 genetic variant
rs4570625 is a risk marker for cognitive impairment. 9-11 Moreover, a significant
association was found between GALM polymorphism and memory, which may imply
SNP rs6741892 as a functional polymorphism in the GALM gene affecting 5-TH
transport.12
The fourth chapter investigated the influence of two candidate gene
polymorphisms (DRD4 and DRD2) in the dopamine system. Executive function and
cognitive flexibility domains were measured by the SCT, CTT A&B and ROCT tests.
Participants were genotyped for polymorphisms in the DRD4 48bp-variable number
tandem repeat (VNTR), DRD2 rs6277 and ANKK1 rs1800497. This study found
significant associations with DRD2 and DRD4 genes and impaired cognition. SNP rs6277
of the DRD2 gene showed a significant association in two cognitive domains (executive
function and cognitive flexibility). DRD4 48bp VNTR (7-allele absent group) was
significantly associated with executive dysfunction, which is in line with a recent
proposal that either higher or lower levels of synaptic dopamine may lead to
neurocognitive impairment.13 In summary, these studies suggest a compounded effect of
genetic influence and HIV infection on cognition in HIV-infected individuals.
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The fifth chapter randomized 284 HIV-infected alcohol abusers to either the
adapted Holistic Health Recovery Program (HHRP-A) or the Health Promotion
Comparison program (HPC). The HHRP-A is based on the IMB model; it is a manualguided intervention designed to reduce sexual transmission risk and alcohol use in HIVinfected alcohol abusers.14 The intervention phase was evaluated at the six-month followup for sexual transmission risk and alcohol use. Results showed a significant decrease for
trading sex for food, money and drugs in men but not in women. Additionally, men and
women exhibited decreased number of sex events following alcohol use. Finally,
cognitive impairment was measured as a moderator for alcohol use. Results showed that
impaired cognitive flexibility and visual memory were associated with increased alcohol
use. This study suggests that HHRP-A is an effective intervention for the reduction of
sexual transmission risk behaviors in HIV-infected alcohol abusers.
Public health genomics is an area of public health that focuses on the effective
translation of genomics research into population health benefits. Genomics plays a role in
most chronic diseases and these chronic diseases are partly the result of how genes
interact with environmental and behavioral risk factors.16-19 Thus better understanding of
the genetic interaction with the environment can help not only clinical practitioners
identify, develop and evaluate screening tools, but this can also help develop
interventions that can improve health and prevent disease.
The evidence for variability in genetic susceptibility to cognitive impairment as
previously demonstrated has laid the groundwork for an approach to intervention
development and implementation informed by genomics which may pave the way to a
more personalized approach to prevention depending on the patient genotype.16 Similarly,
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the outcomes from this dissertation may provide further understanding of how genetic
predispositions influence the neuromodulatory serotonin and dopamine systems relevant
to cognitive impairment and risk behaviors in HIV-infected alcohol abusers. More
personalized treatments including clinical markers, such as cognitive and genetics tests,
may not only assist in determining who is more at risk but, may be able to assist in
determining the type intervention strategies that can be used when a prevention program
is developed and implemented. Interventions that target alcohol use is central to improve
the health of HIV-infected alcohol abusers.15 The HHRP-A intervention program is an
effective method to reduce sexual transmission risk among HIV-infected alcohol abusers.
Enhancing substance abuse treatment with this kind of comprehensive intervention that
addresses the special needs of HIV-infected alcohol abusers is needed and should be
further evaluated.
This dissertation had two main limitations, first, the lack of alpha-level
corrections due to the multiple comparisons that were made, however, these comparisons
were necessary because of the exploratory nature of the studies in this dissertation. Thus,
results should be view with caution and must be replicated. Second, it was not possible to
evaluate the efficacy of the HHRP-A intervention for reducing alcohol use due to the
participants were also active in alcohol or drug abuse treatment programs. Thus, future
studies should include individuals not currently enrolled in a substance abuse treatment
program. Similarly, in the future genetic studies on cognition should include, in addition
to the polymorphisms analyzed in this dissertation, other genes related to cognitive
function since most of the polymorphisms have relative small effects on cognition. In
summary, the results in this dissertation can serve as an initial point for future research in
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cognitive phenotypes for HAND in adults. These findings provide evidence that
dopamine and serotonin polymorphisms influence executive function and memory as
well as moderate alcohol use and that HHRP-A was effective in reducing sexual
transmission risk behaviors in HIV-infected alcohol abusers.
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Appendix 1. HHRP Fact sheet
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Appendix 2. Community-based organizations assessed by the main study
Name

Website

Borinquen Health Care Center

http://www.borinquenhealth.org/

Florida Department of Health:
Broward County Department
Sexually transmitted Disease
Program

http://browardchd.org/default.aspx

Center for Haitian Coalition

http://www.hccinc.org/

South Florida Provider Coalition
Spectrum Programs

http://www.drugrehabcomparison.com/facility
/florida/miami/spectrum-programs-inc-southflorida-provider-coalition/

The Salvation Army

https://donate.salvationarmyusa.org

Care Resource

http://www.careresource.org/

Empower U, Inc.

http://www.empower-u-miami.org/

The Village

http://www.villagesouth.com/

South Florida AIDS Network

http://www.jacksonhealth.org/servicessfan.asp

The Center for Positive Connections
Support & Resource Center
South Beach AIDS Project Inc.

http://www.aidsnet.org/newmain/providers/ce
nterpositive
http://www.miami.com/south-beach-aidsproject-inc

Miami Beach Community Health
Center, Inc.

http://www.miamibeachhealth.org/

Helen B. Bentley Family Health
Center, Inc.

http://www.helenbbentleyfamilyhealthcenter.c
om/
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Appendix 3. Additional Tables for Methods Section
Table 4. Real-time PCR Protocol
Reaction Setup

Per Reaction (μl)

SsoFast™ Probes Supermix 2X

5.00

TaqMan® SNP Genotyping Assay 20X

0.50

DNase-free water

1.50

Template DNA

3.0

Table 5. Cycling Conditions on CFX96 PCR System
Cycling Step

Temperature

Time

No. of Cycles

Denature

95 o C

2 min

Annealing

95 o C

5 sec

Extension

72o C

5 sec

1
49 X
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Table 6. PCR Protocol
Reaction Setup

Per Reaction (μl)

PCR buffer 10X

2.5

dNTP mix

1.0

Primer (forward)

0.5

Primer (reverse)

0.5

Taq DNA polymerase

0.5

DNase-free water

17.0

Template (DNA)

3.0

Table 7. Cycling Conditions on MyCycler PCR System
Cycling Step

Temperature

Time

No. of Cycles

Denature

94o C

30 sec

1

Annealing

60 o C

30 sec

Extension

72o C

2 min

Final Extension

72 o C

2 min
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Appendix 4. Genetic terminology used in this dissertation
Term

Definition

Allele

A known variation (version) of a particular gene

Base pair (bp)

When quantified refers to the physical length of a sequence
of nucleotides

Carrier

A healthy person who is a heterozygote for a recessive trait.

Denaturation

Reversible disruption of hydrogen bonds between
nucleotides converting a double-stranded DNA molecule to
single-stranded molecules. Heating or strong alkali
treatment result in denaturation of DNA.

DNA (deoxyribonucleic

The large double-stranded molecule carrying the genetic

acid)

code. It consists of four bases (adenine, guanine, cytosine
and thymine), phosphate and ribose.

Chromosome

Structure in a cell nucleus that carries the genes.

Gene

Physical and functional unit of heredity that carries
information from one generation to the next, which is the
entire DNA sequence necessary for the synthesis of a
functional polypeptide or RNA molecule. In addition to the
coding regions (exons), a gene may have non-coding
intervening sequences (introns) and transcription-control
regions

Genome-wide

Simultaneous investigation of up to five million genetic

association study

variants covering the whole genome in complex genetic

(GWAS)

diseases.

Genotype

The diploid genetic formula at one or more loci.

Genotype-environment

This term refers both to the modification of genetic risk

(GXE) interaction

factors by environmental risk and protective factors and to
the role of specific genetic risk factors in determining
individual differences in vulnerability to environmental risk
factors
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Appendix 4. Continuation......

Hardy-Weinberg

In an infinitely large population, gene and genotype

equilibrium (HWE)

frequencies remain stable as long as there is no selection,
mutation, or migration. For a bi-allelic locus where the gene
frequencies are p and q: p2+2pq+q2 = 1.

Linkage Disequilibrium

The tendency for two 'alleles' to be present on the same
chromosome (positive LD), or not to segregate together
(negative LD). As a result, specific alleles at two different loci
are found together more or less than expected by chance. The
same situation may exist for more than two alleles. Its
magnitude is expressed as the delta (D) value and corresponds
to the difference between the expected and the observed
haplotype frequency.

MAF

Minor allele frequency (MAF) refers to the frequency at
which the least common allele occurs in a given population.

PCR

Polymerase chain reaction. A technique that allows
amplification of specific DNA segments in a very short time.

rs

Reference SNP ID

SNP

is a single nucleotide change in the DNA sequence code It is
the most common type of stable genetic variation and is biallelic

VNTR

is a linear arrangement of multiple copies of short repeated
DNA sequences that vary in length and are highly
polymorphic, making them useful as markers in genetic
analysis
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